I N T E R P R E TAT I O N FLEX Ready-to-Use Atlas of Stains - 4th Edition A Better Path for Cancer Diagnostics Committed to raising the bar for higher quality During the last decades, organizations such as CAP, UK NEQAS and NordiQC have successfully implemented many initiatives to improve standardization in immunohistochemistry. At the same time, laboratories are striving to deliver accurate clinical diagnostic results while facing and adapting to the increasing number of challenges. It is vital for pathology laboratories to make continuous improvements to maintain the quality of diagnoses, and to be a professional counterpart and key resource to oncologists, and other clinicians. Pathology laboratories face an increasing number of challenges today n Escalating workload due to higher number of immunohistochemistry tests per patient case n Time-consuming procedures n Lack of qualified staff n Healthcare costs - aging population with a corresponding rise in cancer cases - higher number of immunohistochemistry tests per patient case n Low reproducibility and quality issues n Inadequate workflow optimization n Multiple steps of information transcription in various systems While overcoming these challenges, a pathology laboratory must also improve time to diagnosis and reduce error rates, while delivering correct diagnostic results with a high level of certainty that the physician can rely on. At Dako, we are committed to supporting pathology laboratories to overcome these challenges We strive to deliver scientific advancements through leading-edge products and services to facilitate better, more informed decision making in diagnostics. Dako is the first company in the industry, to embed high-quality control concepts into ready-touse procedures. The Dako FLEX Ready-to-Use (RTU) primary antibodies work on formalin-fixed, paraffin-embedded, tissue sections as a set of dedicated reagents for clinical routine diagnostics. The FLEX RTU concept is unique, since it focuses on delivering the correct diagnostic end-result while improving time to diagnosis, reducing manual error rates, and simplifying information retrieval through bar-coded labeling. Equally important, it maintains and delivers reliable staining performance. The Dako FLEX RTU antibody selection, together with the easy-to-use Dako EnVision™ FLEX/ FLEX+ visualization systems provide: nConsistently high diagnostic certainty nEfficient workflow with predictable speed and high capacity nService and support you can rely on for maximum uptime This guide is the product of collaboration with a panel of distinguished experts in the field of pathology. At Dako we work to build lasting partnerships with leading experts to ensure that we optimize the staining performance of our products in line with your demands. Our aim is that this guide will support you on a better path in cancer diagnostics. Dako. A Better Path. For further information on antibody panels and staining performance, we recommend the following references: - Dabbs D et. al., Diagnostic Immunohistochemistry, 3rd Edition, Elsevier, 2006 - Taylor C. R. et. al. Immunomicroscopy, 3rd edition, vol. 19, 2007 - Jasani B. and Schmid K.W, Immunocytochemistry in Diagnostic Histopathology, W.B. Saunders Company, 1993 - The UK NEQAS home page for immunocytochemistry: http://www.ukneqasicc.ucl.ac.uk/ - The NordiQC home page: http://www.nordiqc.org © Copyright 2012 Dako. All rights reserved. No part of this Atlas may be reproduced, copied or transmitted without written permission. Ensuring desired staining performance with the help of an expert panel The FLEX RTU concept was launched in 2008, and the staining performance of the products was developed in collaboration with leading pathologists and their laboratory managers. In the process of ensuring desired staining performance, a panel of these distinguished anatomic pathology experts specified the relevant criteria and reviewed the staining results obtained during development of all the antibodies. During a year-long process, the expert panel specified the required staining performance for each individual antibody. In acknowledging the many contributions we have received, we wish to thank the members of our expert panel and their laboratory managers for sharing their knowledge and insight: From left: Mr. Andrew Dodson, Royal Liverpool University Hospital, UK Prof. Dr. Alvin Martin University of Louisville School of Medicine Department of Pathology, USA Mr. Søren Nielsen Aalborg Hospital , Department of Pathology, Denmark Prof. Dr. Robert Osamura, Tokai University School of Medicine, Japan Dr. Clive Taylor, Keck School of Medicine of USC, USA Ms. Sheron Lear University of Louisville School of Medicine Department of Pathology, USA Dr. David Dabbs, Magee Women’s Hospital, USA Dr. Miguel Piris Centro Nacional de Investigaciones Oncologicas Carlos III, Spain Dr. Kengo Takeuchi, Japanese Foundation for Cancer Research, Japan Prof. Dr. Bharat Jasani, Cardiff University, UK Mrs. Lydia Sánchez Verde Centro Nacional de Investigaciones Oncologicas Carlos III, Spain Dr. Assia Bassarova Radiumhospitalet, Oslo, Norway Dr. John Gosney Royal Liverpool University Hospital, UK Mrs. Kim Mcmanus Magee Women’s Hospital, USA Dr. Jahn Nesland Radiumhospitalet, Oslo, Norway (not in the photo) Based on these guidelines, Dako has developed a standard procedure for all FLEX Ready-to-Use (RTU) primary antibodies that increases productivity without compromising the staining performance accepted by the expert panel. Using the guidelines, this Atlas of Stains provides examples of the staining performance which the panel accepted. The accompanying descriptions are summaries of the written input initially submitted by the expert panel for the guidelines. We also thank Cooperative Human Tissue Network (funded by the National Cancer Institute) for providing valuable human tissues for our studies. Dako will continuously launch new FLEX RTU antibodies, which are directly suited to the needs of pathologist laboratory. The performance and staining of these products have been reviewed and accepted by Dr. Clive Taylor, Keck School of Medicine of USC, USA, Biomedical Scientist Søren Nielsen, Scheme Organizer at NordiQC, Denmark, and Associate Professor Mogens Vyberg, Aarhus University Hospital, Denmark. The new clones will be marked in Atlas of Stains with “NEW”. This Atlas of Stains is by no means intended to override the professional judgment of a certiied pathologist. The contents are provided as information only, and Dako neither claims nor warrants the universal validity of the information provided concerning Differential Diagnosis, as there are national and professional differences in the acceptance of the relevance of various markers. FLEX Ready-to-Use During the past 40 years, immunohistochemistry has become increasingly important in diagnostic pathology, and is now an essential daily tool for cancer diagnosis in most laboratories worldwide. This has led to intense focus on utilizing and expanding IHC for purposes such as implementation of new markers, use of established markers in new areas, and optimization of immunohistochemical techniques. However, IHC is technically complex, and determining what to choose in order to deliver the right results is a major challenge for laboratories. The fact is that there are more than 1 million options when a pathologist sets up a protocol to analyze and report on merely one single antibody! This is why it is so encouraging that Dako has developed the FLEX Ready-to-Use Immunohistochemical System. Dako’s reagents have been set up for use in optimized and streamlined protocols, as a robust backbone for a wide range of diagnostic markers. The system has been designed on the basis of input from IHC experts in surgical pathology who have long and widely acknowledged experience in both general pathology and hematopathology. Input from this large number of IHC experts have been used to align the system and the antibodies to obtain the quality necessary for meeting the demands of routine diagnostic procedures. To obtain appropriate sensitivity and specificity in developing the Ready-to-Use Immunohistochemical System, the performance of each primary antibody has been tested on a wide range of cancers which reflect the diagnostic applications of the specific antibody. Each primary antibody has also been tested on various benign tissues to identify positive controls that could be recommended. Identification of benign tissue for recommended control and the precise description and photographs of microscopic reaction patterns in the Atlas of Stains are truly unique, and will greatly facilitate final quality evaluation of the antibody markers in laboratories. By providing access to a photo gallery and library of detailed information on appropriate controls in the use of antibodies – and how to interpret control and reaction patterns – the Atlas of Stains is destined to become a valuable tool for all laboratories that perform IHC from local clinics and hospitals to large university laboratories. Always remember: There is no Ready-to-Use antibody! There is a Ready-to-Use Immunohistochemical System. To obtain the performance accepted by the surgical experts and portrayed in the Atlas of Stains, the new series of FLEX Ready-to-Use antibodies must be used within the system frames established by Dako. Søren Nielsen Scheme Coordinator, NordiQC Aalborg University Hospital, Denmark How to read the Atlas of Stains The diagnostic staining performance delivered by the Dako FLEX Ready-to Use (RTU) system has been accepted by leading experts in the field and worked out in collaboration with Søren Nielsen, Scheme Organizer at NordiQC. The Dako FLEX RTU procedure makes it possible to deliver a high quality staining performance in all relevant clinical tissues. Information on the antibodies has been organized under the following four headings: nClinical Application nReaction Location nRecommended Control nDifferential Diagnosis The Atlas of Stains illustrates the staining performance of each antibody in the FLEX RTU system and provides examples of: n Staining performance in relevant clinical tissues (See below examples in Figure 1A and 1B and Figure 2A and 2B) n Staining performance in the recommended control tissue (See below examples in Figure 1C and Figure 2C) Table 1. Quality indicators Quality indicator IHC staining intensity High-expression (HE) structures Moderate to strong Low-expression (LE) structures Weak to moderate Figure 1. FLEX RTU Monoclonal Mouse Anti-Human CD79a, Clone JCB117, Code IR621 or IS621. Figure 1A. Precursor B-lymphoblastic leukemia/lymphoma disseminated to testis stained with Anti-CD79a. The majority of the neoplastic cells show a weak to moderate membraneous and cytoplasmic staining reaction. Figure 2. FLEX RTU Monoclonal Mouse Anti-Human Calretinin, Clone DAK-Calret 1, Code IR627 or IS627. Figure 2A. Granulosa cell tumor stained with Anti-Calretinin. The majority of the neoplastic cells show a weak to moderate nuclear and cytoplasmic staining reaction. The code IR/IS refers to: IR = FLEX ready-to-use antibodies for Autostainer Link instruments IS = FLEX ready-to-use antibodies for Dako Autostainer/Autostainer Plus instruments The basis for evaluating the quality of IHC performance is the use of proper controls. Benign tissue that is easily accessible and interpretable is recommended as control for most antibodies in the FLEX RTU system. Accompanying photos illustrate the reaction pattern of the cell types and/or cellular structures which should be identified in the control tissue. These cell types and/or cellular structures should be considered as quality indicators which it is critical to identify in order to monitor appropriate FLEX RTU performance. The quality indicators are divided into high-expression (HE , moderate to strong) and low-expression (LE, weak to moderate) structures. When using the FLEX RTU system on control tissue, it will be normal to find a strong staining in some structures (HE structures) along with a less strong staining in other structures (LE structures). During development, it has been verified that the antigen expression in the vast majority of clinical samples lies within the antigen expression range defined by the HE and LE structures. Please note that for some antibodies only HE structures are identified, and for some antibodies no benign control tissue exists. Because it is calibrated to give optimal staining of HE and LE control structures (Figure 1C and Figure 2C), the FLEX RTU system provides optimal staining in clinical samples with antigen expression ranging from low to high (Figure 1A-1B and Figure 2A-2B). This is why the FLEX RTU system provides highly sensitive IHC performance in a wide range of relevant cancers, and yields IHC results with a high signal-to-noise ratio that facilitates interpretation. HE LE Figure 1B. Plasmacytoma stained with Anti-CD79a. The majority of the neoplastic cells show a strong cytoplasmic staining reaction. Figure 1C. Tonsil stained with Anti-CD79a. The mantle/marginal zone B cells are HE structures showing a moderate to strong membraneous and cytoplasmic staining reaction, while the germinal center B cells are LE structures showing a moderate, but distinct staining reaction. Plasma cells show a strong cytoplasmic staining reaction. The encircled cells/cellelular structures are representatives of the HE and LE structures. HE LE Figure 2B. Epithelial mesothelioma stained with Anti-Calretinin. The majority of the neoplastic cells show a strong nuclear and cytoplasmic staining reaction. Figure 2C. Colon stained with Anti-Calretinin. The peripheral nerves show a distinct nuclear and cytoplasmic staining reaction. The ganglion cells are HE structures with a moderate to strong staining reaction, whereas the axons are LE structures that are weak to moderately stained. The encircled cells/cellelular structures are representatives of the HE and LE structures. ATLAS OF STAINS FLEX Ready-to-Use Table of Contents Actin (Muscle), Clone HHF35 . . . . . . . . . . . . . . . . . . . . . . . . . . . Alpha-1-Antitrypsin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Alpha-1-Fetoprotein. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . AMACR (P504S), Clone 13H4 . . . . . . . . . . . . . . . . . . . . . . . . . . Amyloid A, Clone mc1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B-Cell-Specific Activator Protein, Clone DAK-Pax5 . . . . . . . BCL2 Oncoprotein, Clone 124 . . . . . . . . . . . . . . . . . . . . . . . . . BCL6 Protein, Clone PG-B6p . . . . . . . . . . . . . . . . . . . . . . . . . . Beta-Catenin, Clone ß-Catenin-1 . . . . . . . . . . . . . . . . . . . . . . . CA 125, Clone M11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Calcitonin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Caldesmon, Clone h-CD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Calretinin, Clone DAK-Calret 1 . . . . . . . . . . . . . . . . . . . . . . . . . Carcinoembryonic Antigen, Clone II-7 . . . . . . . . . . . . . . . . . . . Carcinoembryonic Antigen (CEA) . . . . . . . . . . . . . . . . . . . . . . . CD1a, Clone O10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD2, Clone AB75 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD4, Clone 4B12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . NEW CD5, Clone 4C7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD7, Clone CBC.37 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD8, Clone C8/144B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD10, Clone 56C6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD15, Clone Carb-3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD19, Clone LE-CD19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD20cy, Clone L26 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD21, Clone 1F8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . NEW CD23, Clone DAK-CD23 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD30, Clone Ber-H2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD31, Endothelial Cell, Clone JC70A . . . . . . . . . . . . . . . . . . . CD34 Class II, Clone QBEnd 10 . . . . . . . . . . . . . . . . . . . . . . . . CD43, Clone DF-T1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD45, Leucocyte Common Antigen, Clone 2B11 + PD7/26 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD56, Clone 123C3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD57, Clone TB01 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD68, Clone KP1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD68, Clone PG-M1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD79a, Clone JCB117 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD99, MIC2 Gene Products, Ewing’s Sarcoma Marker, Clone 12E7 . . . . . . . . . . . . . . . . . . . CD138, Clone MI15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CD246, ALK Protein, Clone ALK1 . . . . . . . . . . . . . . . . . . . . . . CDX-2, Clone DAK-CDX-2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chorionic Gonadotropin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chromogranin A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . NEW Cyclin D1, Clone EP12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokeratin, Clone AE1/AE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokeratin 5/6, Clone D5/16 B4 . . . . . . . . . . . . . . . . . . . . . . . Cytokeratin 7, Clone OV-TL12/30 . . . . . . . . . . . . . . . . . . . . . . Cytokeratin 17, Clone E3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokeratin 18, Clone CD10 . . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokeratin 19, Clone RCK108 . . . . . . . . . . . . . . . . . . . . . . . . . Cytokeratin 20, Clone Ks20.8 . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokeratin, High Molecular Weight, Clone 34βE12 . . . . . . . 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 NEW NEW NEW NEW NEW NEW  Currently unavailable in the US.  Not available in the US. Cytomegalovirus, Clone CCH2 + DDG9 . . . . . . . . . . . . . . . 63 D2-40, Clone D2-40 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 Desmin, Clone D33 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 E-Cadherin, Clone NCH-38 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 Epithelial Antigen, Clone Ber-EP4 . . . . . . . . . . . . . . . . . . . . . . . 67 Epithelial Membrane Antigen, Clone E29 . . . . . . . . . . . . . . . . 68 Epstein-Barr Virus, LMP-1, Clone CS.1-4 . . . . . . . . . . . . . . 69 Ets-Related Gene (ERG), Clone EP111 . . . . . . . . . . . . . . . . . . 70 Estrogen Receptor a, Clone 1D5 . . . . . . . . . . . . . . . . . . . . . . . 71 Estrogen Receptor a, Clone EP1 . . . . . . . . . . . . . . . . . . . . . . 72 Gastrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 GCDFP-15, Clone 23A3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Glial Fibrillary Acidic Protein . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 Helicobacter Pylori . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 Hepatocyte, Clone OCH1E5 . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Herpes Simplex Virus Type 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 IgD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 IgG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 IgM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Inhibin-a, Clone R1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Kappa Light Chains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 Ki-67 Antigen, Clone MIB-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 Lambda Light Chains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 Mammaglobin, Clone 304-1A5 . . . . . . . . . . . . . . . . . . . . . . . . 87 Mast Cell Tryptase, Clone AA1 . . . . . . . . . . . . . . . . . . . . . . . . . 88 Melan-A, Clone A10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 Melanosome, Clone HMB45 . . . . . . . . . . . . . . . . . . . . . . . . . . 90 MUC2, Clone CCP58 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91 MUM1 Protein, Clone MUM1p . . . . . . . . . . . . . . . . . . . . . . . . . 92 MutL Protein Homolog 1 (MLH1), Clone ES05 . . . . . . . . . . . 93 MutS Protein Homolog 2 (MSH2), Clone FE11 . . . . . . . . . . . 94 MutS Protein Homolog 6 (MSH6), Clone EP49 . . . . . . . . . . . 95 Myeloperoxidase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 Myogenin, Clone F5D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97 Neurofilament Protein, Clone 2F11 . . . . . . . . . . . . . . . . . . . . . . 98 Neuron-Specific Enolase, Clone BBS/NC/VI-H14 . . . . . . . . . 99 Nucleophosmin, Clone 376 . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 p53 Protein, Clone DO-7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101 Placental Alkaline Phosphatase, Clone 8A9 . . . . . . . . . . . . . 102 Pneumocystis Jiroveci, Clone 3F6 . . . . . . . . . . . . . . . . . . . . . 103 Postmeiotic Segregation Increased 2 (PMS2), Clone EP51 . . . . . . . 104 Progesterone Receptor, Clone PgR 636 . . . . . . . . . . . . . . . . 105 Prostate-Specific Antigen . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 Renal Cell Carcinoma, Clone SPM314 . . . . . . . . . . . . . . . . . 107 S100 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 Smooth Muscle Actin, Clone 1A4 . . . . . . . . . . . . . . . . . . . . . . 109 Smooth Muscle Myosin Heavy Chain, Clone SMMS-1 . . . 110 Synaptophysin, Clone SY38 . . . . . . . . . . . . . . . . . . . . . . . . . . 111 Terminal Deoxynucleotidyl Transferase (TdT) . . . . . . . . . . . . 112 Thyroglobulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113 Thyroid Transcription Factor (TTF-1), Clone 8G7G3/1 . . . . 114 Tyrosinase, Clone T311. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 Villin, Clone 1D2 C3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 Vimentin, Clone V9 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117 Von Willebrand Factor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118 Wilms’ Tumor 1 (WT1) Protein, Clone 6F-H2 . . . . . . . . . . . . 119 ZAP-70, Clone 2F3.2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120 Antibody: Monoclonal Mouse Anti-Human Actin (Muscle) Clone: HHF35 Code: IR700 or IS700 Clinical Application Reaction Location Recommended Control For identification of soft tissue tumors with muscle differentiation, i.e. leiomyoma, leiomyosarcoma (Fig. A) and rhabdomyosarcoma (Fig. B). Cytoplasm. Appendix/Colon: All the smooth muscle cells in vessel walls, muscle layers and lamina muscularis mucosa should show a moderate to strong cytoplasmic staining reaction. The fine layer of myoepithelial cells delineating the surface epithelial cells should be demonstrated. No staining reaction should be seen in the epithelial cells (Fig. C). Tongue: Myoepithelial cells of the mucous/salivary glands should show a weak to moderate staining reaction (Fig. D). No staining should be seen in the epithelial cells. Differential Diagnosis* 1. Leiomyosarcoma vs. carcinoma. 2. Rhabdomyosarcoma vs. other malignant mesenchymal tumors. * Differential diagnosis is aided by the results from a panel of antibodies. 10 Figure A. Leiomyosarcoma. The majority of the neoplastic cells show a moderate to strong staining reaction. Figure B. Rhabdomyosarcoma. The majority of the neoplastic cells show a weak to moderate staining reaction. Figure C. Colon. All the smooth muscle cells in vessel walls, lamina muscularis mucosa and myoepithelial cells around colonic crypts show a moderate to strong staining reaction. Figure D. Tongue. The myoepithelial cells of the mucous/salivary glands show a weak to moderate staining reaction. Antibody: Polyclonal Rabbit Anti-Human Alpha-1-Antitrypsin Code: IR505 or IS505 Clinical Application Reaction Location Recommended Control Primarily for identification of alpha-1-antitrypsin (A1AT) accumulation in the hepatocytes of A1AT deficient liver (Fig. A). Cytoplasm. Tonsil: The germinal center macrophages of the secondary follicles should show a moderate to strong staining reaction and neutrophil granulocytes should show a weak to moderate distinct coarse granular cytoplasmic staining reaction (Fig. B). Liver: The Kupffer cells should show a moderate to strong distinct granular staining reaction, while the hepatocytes should be negative or show a weaker granular cytoplasmic staining reaction (Fig. C). Differential Diagnosis* Granular cell tumor vs. histiocytic skin reaction. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. A1AT deficient liver. The hepatocytes with alpha-1-antitrypsin deficiency show a strong granular cytoplasmic staining reaction (seen in a standard HE stained slide as an accumulation of eosinophilic lysosomes), while normal hepatocytes show a weak staining reaction. Figure B. Tonsil. The germinal center macrophages show a moderate to strong and the neutrophils a weak to moderate staining reaction. Figure C. Liver. The Kupffer cells show a moderate to strong distinct granular staining reaction, while the hepatocytes show a weak and diffuse cytoplasmic staining reaction. 11 Antibody: Polyclonal Rabbit Anti-Human Alpha-1-Fetoprotein Code: IR500 or IS500 Clinical Application Reaction Location Recommended Control Differential Diagnosis* Primarily for identification of hepatocellular carcinoma, hepatoid tumor, and germ cell tumors of the testis and ovary such as yolk sac tumor (Fig. A) and embryonal carcinoma (Fig. B and Fig. C). Cytoplasm. Embryonal carcinoma: Focally, the neoplastic cells should show a moderate to strong cytoplasmic staining reaction with minimal background staining (Fig. B and Fig. C). 1. Yolk sac tumor vs. clear cell carcinoma. 2. Embryonal carcinoma vs. testicular seminoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Yolk sac tumor. The neoplastic cells show a focal and distinct cytoplasmic staining reaction. Figure C. Embryonal carcinoma. The neoplastic cells show a moderate to strong cytoplasmic staining reaction. 12 Figure B. Embryonal carcinoma. The neoplastic cells show a focal and distinct cytoplasmic staining reaction. Antibody: Monoclonal Rabbit Anti-Human AMACR (P504S) Clone: 13H4 Code: IR060 or IS060 Clinical Application Reaction Location Recommended Control For identification of prostate adenocarcinoma. The majority of the prostatic adenocarcinoma cells should show a granular cytoplasmic staining reaction (Fig. A and Fig. B). Cytoplasm. Prostate adenocarcinoma: The majority of the carcinoma cells should show a moderate to strong granular cytoplasmic staining reaction. Benign prostatic hyperplasia: The epithelial cells of the hyperplastic prostate glands should be negative or only focally show a weak granular cytoplasmic staining reaction (Fig. C). Differential Diagnosis* Prostatic adenocarcinoma vs. benign prostatic lesion. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Prostate adenocarcinoma. The majority of the carcinoma cells show a distinct granular cytoplasmic staining reaction and the benign glands are mostly negative. Figure B. Prostate adenocarcinoma. The majority of the carcinoma cells show a distinct granular cytoplasmic staining reaction. A spotty granular cytoplasmic staining is also seen in a few cells of the benign glands. Figure C. Prostate. The hyperplastic glands show a weak granular cytoplasmic staining reaction. 13 Antibody: Monoclonal Mouse Anti-Human Amyloid A Clone: mc1 Code: IR605 or IS605 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification and classification of AA-amyloidosis (Fig. A to Fig. C). Extracellular and cytoplasm. Kidney with amyloidosis: The smooth muscle cells in the vessels and in the glomerular capillary network should show a moderate to strong cytoplasmic staining reaction, while the basal membrane of the renal glomeruli should show a weak to moderate staining reaction (Fig. C). AA-amyloidosis vs. other types of amyloidosis or inflammatory disease. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon with amyloidosis. The smooth muscle cells in the vessels show a weak staining reaction. 14 Figure C. Kidney with amyloidosis. The smooth muscle cells in the vessels and in the glomerular capillary network show a moderate to strong cytoplasmic staining reaction, while the basal membrane of the renal glomeruli show a weak to moderate staining reaction. Figure B. Appendix with amyloidosis. The smooth muscle cells in the vessels show a strong staining reaction. Antibody: Monoclonal Mouse Anti-Human B-Cell-Specific Activator Protein Clone: DAK-Pax5 Code: IR650 or IS650 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of pro/pre B cells, mature B cells and in the classification of lymphomas (Fig. A and Fig. B). Nuclear. Tonsil: Virtually all B cells should show a moderate to strong nuclear staining reaction. A weak to moderate cytoplasmic staining reaction can be seen in germinal center B cells (Fig. C). No staining reaction should be seen in plasma cells or in the squamous epithelial cells. 1. B-cell lymphoma vs. T-cell lymphoma. 2. Identification of Reed-Sternberg cells in classic Hodgkin lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Hodgkin lymphoma. The Reed-Sternberg cells show a weak to moderate nuclear staining reaction. Figure B. B-cell chronic lymphatic leukemia/small lymphocytic lymphoma. The majority of the neoplastic cells show a moderate to strong nuclear staining reaction. Figure C. Tonsil. The B cells in the mantle zone and in the germinal center show a moderate to strong nuclear staining reaction. The germinal center B cells also show a weak cytoplasmic staining reaction. 15 Antibody: Monoclonal Mouse Anti-Human BCL2 Oncoprotein Clone: 124 Code: IR614 or IS614 Clinical Application Reaction Location Primarily for identification of follicular lymphoma (Fig. A). Various B- and T-cell lymphoproliferative diseases and some diffuse large B-cell lymphomas are BCL-2 positive. Burkitt lymphoma /leukemia is generally negative for BCL-2 (Fig. B). Cytoplasm. Recommended Control Tonsil: The scattered T cells in the germinal centers and the mantle zone B cells should show a moderate to strong cytoplasmic staining reaction. The germinal center B cells should be negative (Fig. C). The basal epithelial cells should show a weak to moderate staining reaction (Fig. D). Differential Diagnosis* 1. Follicular lymphoma vs. Burkitt lymphoma/leukemia. 2. Follicular lymphoma vs. reactive germinal center. 3. Diffuse large B-cell lymphoma mimicking Burkitt lymphoma/leukemia vs. Burkitt lymphoma/ leukemia. * Differential diagnosis is aided by the results from a panel of antibodies. 16 Figure A. Follicular lymphoma. The majority of the neoplastic cells show a distinct cytoplasmic staining reaction. Figure B. Burkitt lymphoma/leukemia. The neoplastic cells are negative for BCL2 and only benign T cells are stained. Figure C. Tonsil. The scattered T cells in the germinal centers and the mantle zone B cells show a moderate to strong cytoplasmic staining reaction. The germinal center B cells are negative. Figure. D. Tonsil. The basal epithelial cells show a weak to moderate staining reaction. Antibody: Monoclonal Mouse Anti-Human BCL6 Protein Clone: PG-B6p Code: IR625 or IS625 Clinical Application Reaction Location For classification of diffuse large B-cell lymphomas (Fig. A), follicular lymphomas (Fig. B) and Burkitt lymphoma/leukemia. Nucleus. Recommended Control Tonsil: The majority of the germinal center B cells should show a moderate to strong nuclear staining reaction (Fig. C). The squamous epithelial cells should show a weak to moderate nuclear staining reaction (Fig. D). Differential Diagnosis* Diffuse large B-cell lymphoma/follicular lymphoma vs. mantle cell lymphoma/MALT lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Diffuse large B-cell lymphoma (germinal center subtype). The majority of the neoplastic cells show a distinct nuclear staining reaction. Figure B. Follicular lymphoma. The majority of the neoplastic cells show a distinct nuclear staining reaction. Figure C. Tonsil. The majority of the germinal center B cells show a moderate to strong nuclear staining reaction. Figure. D. Tonsil. The squamous epithelial cells show a weak to moderate nuclear staining reaction. 17 Antibody: Monoclonal Mouse Anti-Human Beta-Catenin Clone: ß-Catenin-1 Code: IR702 or IS702 Clinical Application Reaction Location Recommended Control For identification of desmoid tumors, colorectal cancer (Fig. A) and colon adenoma (Fig. B). Membrane, cytoplasm and/or nuclear. Appendix/Colon: The epithelial cells should show a moderate to strong predominantly membranous staining reaction (a weak cytoplasmic reaction is accepted) (Fig. C). A weak membranous reaction can be seen in scattered endothelial cells, satellite cells in peripheral nerves and in the follicular dendritic network in the germinal centers of lymph nodes. Liver: The hepatocytes should show a weak to moderate predominantly membranous staining reaction (Fig. D). Differential Diagnosis* 1. Desmoid tumor vs. gastrointestinal stromal tumor. 2. Normal colon vs. colon adenoma and adenocarcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. 18 Figure A. Colon adenocarcinoma. Many of the neoplastic cells show a moderate to strong nuclear staining reaction, while the normal epithelial cells show a membranous staining reaction. Figure B. Colon adenoma. The majority of the dysplastic cells show a moderate to strong nuclear staining reaction with weaker costaining of cytoplasm. Figure C. Colon. The epithelial cells show a moderate to strong predominantly membranous staining reaction. Figure D. Liver. The hepatocytes show a weak to moderate predominantly membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CA 125 Clone: M11 Code: IR701 or IS701 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of serous ovarian carcinoma (Fig. A) and mesothelioma (Fig. B). Membrane and cytoplasm. Fallopian tube: The apical brush border of the majority of the epithelial cells should show a moderate to strong predominantly membranous staining reaction (Fig. C). 1. Ovarian adenocarcinoma vs. other adenocarcinoma. 2. Mesothelioma vs.other tumor, e.g. melanoma and lung adenocarcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Serous ovarian carcinoma. The majority of the neoplastic cells show a moderate to strong predominantly membranous staining reaction. Figure B. Mesothelioma. A significant porportion of the neoplastic cells show a moderate to strong predominantly membranous staining reaction. Figure C. Fallopian tube. The apical brush border of the epithelial cells shows a moderate to strong predominantly membranous staining reaction. 19 Antibody: Polyclonal Rabbit Anti-Human Calcitonin Code: IR515 or IS515 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of thyroid medullary carcinoma (Fig. A and Fig. B) and thyroid C cells (Fig. C). Cytoplasm. Thyroid: Scattered as single cells among normal thyroid follicles, the parafollicular C cells should show a moderate to strong distinct granular cytoplasmic staining reaction (Fig. C). Thyroid medullary carcinoma vs. thyroid follicular carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Thyroid medullary carcinoma. The neoplastic cells show a strong staining reaction for calcitonin. Figure C. Thyroid. A thyroid C cell showing a strong cytoplasmic staining reaction. 20 Figure B. Thyroid medullary carcinoma. The neoplastic cells show a strong cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Caldesmon Clone: h-CD Code: IR054 or IS054 Clinical Application Reaction Location Recommended Control For identification of smooth muscle and tumors with smooth muscle origin such as leiomyosarcoma (Fig. A), leiomyoma (Fig. B), angioleiomyoma and glomus tumor. Cytoplasm. Appendix/Colon: The smooth muscle cells in the blood vessels, muscularis mucosa and lamina muscularis propria should show a moderate to strong distinct cytoplasmic staining reaction (Fig. C). Normal breast or breast with hyperplasia: The myoepithelial cells around the ducts and lobules should show a moderate to strong cytoplasmic staining reaction and no reaction of epithelial cells. Muscle cells in blood vessels should show a strong cytoplasmic staining reaction. Differential Diagnosis* 1. Uterine leiomyosarcoma vs. carcinoma. 2. Uterine leiomyosarcoma vs. endometrial stromal sarcoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Leiomyosarcoma. The neoplastic cells show a strong cytoplasmic staining reaction - the intensity can vary from weak to strong. Figure B. Leiomyoma. The neoplastic cells and smooth muscle cells of small blood vessel wall (lower right corner) show a strong cytoplasmic staining reaction. Figure C. Appendix. The smooth muscle cells show a moderate to strong cytoplasmic staining reaction. 21 Antibody: Monoclonal Mouse Anti-Human Calretinin Clone: DAK-Calret 1 Code: IR627 or IS627 Clinical Application Reaction Location Recommended Control Differential Diagnosis* Primarily for identification of mesothelial cells and malignant mesothelioma of the epithelial type (Fig. A) and in the differential diagnosis of mesothelioma vs. primary/metastatic lung or ovarian adenocarcinoma. Other tumors such as granulosa cell tumor also express calretinin (Fig. B). Nucleus and cytoplasm. Appendix/Colon: The peripheral nerves should show a distinct nuclear and cytoplasmic staining reaction. The staining reaction in ganglion cells should be moderate to strong, whereas the axons should be weakly to moderately stained (Fig. C). Peripheral macrophages should also show a nuclear and cytoplasmic staining reaction. No staining should be seen in the epithelial cells. 1. Mesothelioma vs. carcinoma. 2. Adenomatoid tumor vs. hemangioma. 3. Sex cord stromal tumor vs. ovarian epithelial tumor. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Epithelial mesothelioma. The majority of the neoplastic cells show a distinct nuclear and cytoplasmic staining reaction. Figure C. Colon. The ganglion cells show a strong staining reaction and the axons show a weak to moderate staining reaction. 22 Figure B. Granulosa cell tumor. The majority of the neoplastic cells show a distinct nuclear and cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Carcinoembryonic Antigen Clone: II-7 Code: IR622 or IS622 Clinical Application Reaction Location Recommended Control For identification of carcinoembryonic antigen (CEA)-positive glycocalyx surface of gastrointestinal cells and colon carcinoma (Fig. A). CEA is expressed by various tumors such as lung adenocarcinoma, meningioma and medullary carcinoma of the thyroid (Fig. B). Membrane and cytoplasm. Appendix/Colon: The epithelial cells of the appendical mucosa should show a moderate to strong cytoplasmic staining reaction. At the luminal surface and the glycocalyx, the staining is stronger than cells in the basal layer. Both compartments should be demonstrated (Fig. C). Tonsil: The squamous epithelial cells should, focally, show a weak to moderate cytoplasmic staining reaction. If well preserved, 2/3 of the upper layer should be demonstrated (Fig. D). Differential Diagnosis* 1. Colorectal carcinoma vs. ovarian carcinoma. 2. Colorectal carcinoma vs. prostatic carcinoma. 3. Thyroid medullary carcinoma vs. thyroid follicular carcinoma. 4. Urothelial carcinoma vs. renal cell carcinoma. 5. Pancreatic ductal carcinoma vs. acinic cell carcinoma. (For hepatocellular carcinoma, polyclonal CEA should be used). * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma. The majority of the neoplastic cells show a distinct and predominantly cytoplasmic staining reaction. Figure B. Medullary carcinoma of thyroid. The neoplastic cells show a strong membranous and cytoplasmic staining reaction. Figure C. Colon. The epithelial cells of the appendical mucosa show a moderate to strong cytoplasmic staining reaction. At the luminal surface and the glycocalyx, the staining is stronger than in cells in the basal layer. Figure D. Tonsil. Focally, the squamous epithelial cells show a weak to moderate cytoplasmic staining reaction. 23 Antibody: Polyclonal Rabbit Anti-Human Carcinoembryonic Antigen (CEA) Code: IR526 or IS526 Clinical Application Reaction Location Recommended Control For identification of the histogenesis of epithelial tumors in several morphological categories (Fig. A and Fig. B). Membrane and cytoplasm. Liver: The bile canaliculi should show a moderate to strong membranous staining reaction (Fig. C). No staining reaction should be seen in hepatocytes or only a weak, diffuse cytoplasmic staining reaction. Pancreas: Intercalated ducts/acinar ducts should show a weak to moderate membranous staining reaction (Fig. D). Differential Diagnosis* 1. Hepatocellular carcinoma vs. cholangiocarcinoma. 2. Hepatocellular carcinoma vs. metastatic carcinoma spread to the liver. * Differential diagnosis is aided by the results from a panel of antibodies. 24 Figure A. Hepatocellular carcinoma. The bile canaliculi show a distinct moderate staining reaction. Figure B. Secondary adenocarcinoma spread to the liver. The neoplasic cells show a moderate to strong staining reaction, and in the surrounding liver tissue the bile canaliculi show a distinct staining reaction. Figure C. Liver. The bile canaliculi show a moderate to strong membranous staining reaction. Figure D. Pancreas. The acinar ducts show a weak membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CD1a Clone: O10 Code: IR069 or IS069 Clinical Application Reaction Location Recommended Control For identification of thymoma (Fig. A), precursor T-lymphoblastic leukemia/lymphoma and Langerhans’ cell histiocytosis. Membrane and cytoplasm. Tonsil or skin: The Langerhans’ cells in the squamous epithelium should show a moderate to strong predominantly membranous staining reaction (Fig. B). The epithelial cells should be negative. Thymus: The cortical thymocytes should show a moderate to strong predominantly membranous staining reaction (Fig. C). Differential Diagnosis* T-cell lymphoblastic lymphoma vs. mature T-cell lymphoma or B-cell neoplasm. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Thymoma. Lymphoblasts intermingled with negative epithelial cells of the thymoma show a strong predominantly membranous staining reaction. Figure B. Skin. The Langerhans’ cells in the squamous epithelium show a moderate to strong predominantly membranous staining. Figure C. Thymus. The cortical thymocytes show a strong predominantly membranous staining reaction. 25 Antibody: Monoclonal Mouse Anti-Human CD2 Clone: AB75 Code: IR651 or IS651 Clinical Application Reaction Location Recommended Control For identification of normal T cells and related neoplasms such as precursor T-lymphoblastic leukemia/lymphoma (Fig. A), peripheral T-cell lymphoma (Fig. B) and anaplastic large cell lymphoma. Membrane and cytoplasm. Tonsil: Virtually all T cells and NK cells should show a predominantly membranous and cytoplasmic staining reaction. The crowded T cells in the T-zone should show a moderate to strong continuous membranous staining reaction. The scattered T cells in the germinal center should show a strong continuous membranous staining reaction (Fig. C and D). Appendix/Colon: Intraepithelial T cells in the epithelium should show a moderate to strong staining reaction. Differential Diagnosis* T-cell lymphoma vs. B-cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. 26 Figure A. Precursor T-lymphoblastic leukemia/lymphoma. The majority of the neoplastic cells show a distinct predominantly membranous staining reaction. Figure B. Peripheral T-cell lymphoma. The majority of the neoplastic cells show a distinct predominantly membranous staining reaction. Figure C. Tonsil. The crowded T cells in the T-zone show a moderate to strong membranous staining reaction, and the scattered T cells in the germinal center show a strong continuous membranous staining reaction. Figure D. Tonsil. The crowded T cells in the T-zone show a moderate to strong membranous staining reaction, and the scattered T cells in the germinal center show a strong continuous membranous staining reaction. Antibody: Polyclonal Rabbit Anti-Human CD3 Code: IR503 or IS503 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of T cells and their neoplasms such as T- and/or NK-cell lymphomas (Fig. A and Fig. B) and mycosis fungoides. Membrane and cytoplasm. Tonsil: Virtually all T cells should show a predominantly membranous and weaker cytoplasmic staining reaction. Both the crowded T cells in the T-zone and the scattered T cells in the germinal center should show a moderate to strong staining reaction (Fig. C). T- or NK-cell neoplasms vs. other neoplasms. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Peripheral T-cell lymphoma. The majority of the neoplastic cells show a distinct membranous and cytoplasmic staining reaction. Figure B. Precursor T-lymphoblastic leukemia/lymphoma. The majority of the neoplastic cells show a distinct staining reaction - predominantly membranous, but may be cytoplasmic. Figure C. Tonsil. The crowded T cells in the T-zone and the scattered T cells in the germinal center show a moderate to strong staining reaction. 27 Antibody: Monoclonal Mouse Anti-Human CD4 Clone: 4B12 Code: IR649 or IS649 Clinical Application Reaction Location Recommended Control For identification of thymocytes, T-helper cells and related tumors such as peripheral T-cell lymphoma (unspecified) (Fig. A), anaplastic large cell lymphoma (Fig. B) and mycosis fungoides. Membrane. Tonsil: The T-helper cells should show a moderate to strong distinct membranous staining reaction. Both the crowded T-helper cells in the T-zone and the scattered T-helper cells in the germinal center should be demonstrated (Fig. C). Liver: Kupffer cells and the endothelial cells of the liver sinusoids should show a weak to moderate staining reaction, while the hepatocytes should be negative (Fig. D). Differential Diagnosis* 1. T-cell lymphoma vs. B-cell lymphoma. 2. Subtyping of T-cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. 28 Figure A. Peripheral T-cell lymphoma. The majority of the neoplastic cells show a strong distinct membranous staining reaction. Figure B. Anaplastic large cell lymphoma. The majority of the neoplastic cells show a strong distinct membranous staining reaction. Figure C. Tonsil. The crowded T-helper cells in the T-zone and the scattered T-helper cells in the germinal center show a moderate to strong staining reaction. Figure D. Liver. Kupffer cells and the endothelial cells of the liver sinusoids show a weak to moderate staining reaction. Antibody: Monoclonal Mouse Anti-Human CD5 Clone: 4C7 Code: IR082 or IS082 NEW Clinical Application Reaction Location For identification of B-and T-cell malignancies including B-cell chronic lymphoid leukemia/ small lymphocytic lymphoma, mantle cell lymphoma (Fig. A) and T-cell lymphoma and leukemia. Membrane and/or cytoplasmic. Recommended Control Tonsil: Virtually all T cells should show a moderate to strong membranous, but also cytoplasmic reaction (Fig. B). The crowded T cells in the T-zone and the scattered T cells in the germinal center should be distinctively demonstrated and show a continuous membranous staining reaction. In the mantle zone, a weak membranous staining reaction should be seen in scattered B cells, but these B cells may be difficult to distinguish from more strongly stained T cells that also are present. Differential Diagnosis* B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma and mantle cell lymphoma vs. follicular cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Mantle cell lymphoma. The neoplastic cells show a moderate to strong membraneous staining reaction. Figure B. Tonsil. The crowded T cells in the T-zone and the scattered T cells in the germinal center should show a moderate to strong staining reaction. 29 Antibody: Monoclonal Mouse Anti-Human CD7 Clone: CBC.37 Code: IR643 or IS643 Clinical Application Reaction Location Recommended Control For identification of T-cell lymphoma (Fig. A and Fig. B). Membrane. Tonsil: Virtually all T cells should show a predominantly membranous staining reaction. The crowded T cells in the T- zone should show a strong continuous membranous reaction and the scattered T cells in the germinal center should show a moderate to strong staining reaction (Fig. C). Appendix/Colon: The intraepithelial T cells should show a moderate to strong distinct staining reaction, while the epithelial cells should be negative (Fig. D). Differential Diagnosis* 1. T-cell lymphoma vs. B-cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. 30 Figure A. Precursor T-lymphoblastic leukemia/lymphoma. The majority of the neoplastic cells show a strong membranous staining reaction. Figure B. Peripheral T-cell lymphoma. The majority of the neoplastic cells show a strong membranous staining reaction. Figure C. Tonsil. The crowded T cells in the T- zone show a strong continuous membranous staining reaction and the scattered T cells in the germinal center show a moderate to strong staining reaction. Figure D. Appendix. The intraepithelial T cells show a moderate to strong distinct staining reaction, while the epithelial cells are negative. Antibody: Monoclonal Mouse Anti-Human CD8 Clone: C8/144B Code: IR623 or IS623 Clinical Application Reaction Location Recommended Control For identification of cytotoxic/suppressor T cells and their neoplastic counterparts (Fig. A). Membrane and cytoplasm. Tonsil: In the interfollicular zone, approximately 30-40% of the T cells should show a moderate to strong predominantly membranous staining reaction (Fig. B). Spleen: The sinusoidal lining cells should show a weak to moderate staining reaction. (Fig. C). Differential Diagnosis* 1. T-cell lymphoma vs. B-cell lymphoma. 2. Subtyping of T-cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Peripheral T-cell lymphoma. Focally, the neoplastic cells show a moderate to strong cytoplasmic and membraneous staining reaction. Figure B. Tonsil. T cells in the interfollicular zone show a moderate to strong predominantly membranous staining reaction. Figure C. Spleen. The sinusoidal lining cells show a weak to moderate staining reaction, and scattered T cells show a strong staining reaction. 31 Antibody: Monoclonal Mouse Anti-Human CD10 Clone: 56C6 Code: IR648 or IS648 Clinical Application Reaction Location Recommended Control For identification of Burkitt lymphoma/leukemia, follicular lymphoma (except grade III), precursor B-cell lymphoblastic leukemia/lymphoma (Fig. A) and renal cell carcinoma of the clear cell type (Fig. B). Membrane. Liver: The bile canaliculi should show a moderate to strong distinct staining reaction with minimal staining reaction in the hepatocytes (Fig. C). Tonsil: Virtually all the germinal center cells should show a weak to moderate predominantly membranous staining reaction. The neutrophils should show a membranous staining reaction, while all the peripheral lymphocytes should be negative (Fig. D). Differential Diagnosis* 1. Follicular lymphoma vs. other low grade/small to medium-sized B-cell lymphomas such as mantle cell lymphoma and MALT lymphoma. 2. Renal cell carcinoma (clear cell type) vs. other clear cell type neoplasms. 3. Endometrial stromal sarcoma vs. uterine leiomyosarcoma. * Differential diagnosis is aided by the results from a panel of antibodies. 32 Figure A. Precursor B-cell lymphoblastic leukemia/lymphoma. The neoplastic cells show a strong membranous staining reaction. Figure B. Renal cell carcinoma (clear cell type). Focally, the neoplastic cells show a moderate membranous staining reaction. Figure C. Liver. The bile canaliculi should show a moderate to strong distinct staining reaction with minimal staining reaction in the hepatocytes. Figure D. Tonsil. The germinal center cells show a weak to moderate predominantly membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CD15 Clone: Carb-3 Code: IR062 or IS062 Clinical Application Reaction Location Recommended Control For identification of mononuclear Hodgkin cells and Reed-Sternberg cells in Hodgkin lymphoma (Fig. A). This antibody also labels lung adenocarcinoma (Fig. B). Membrane and cytoplasm. Lymph node with Hodgkin lymphoma: Hodgkin cells and the Reed-Sternberg cells show a distinct membranous and cytoplasmic staining reaction (Fig. A). Kidney: Both the proximal and distal tubules should show a weak to strong distinct and predominantly membranous and cytoplasmic staining reaction (Fig. C). Tonsil: The neutrophils, eosinophils and macrophages should show a moderate to strong granular cytoplasmic staining reaction (Fig. D). Differential Diagnosis* 1. Hodgkin lymphoma vs. thymoma. 2. Hodgkin lymphoma vs. T-cell-rich B-cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Hodgkin lymphoma. The majority of the Hodgkin cells and the Reed-Sternberg cells show a distinct membranous staining reaction and cytoplasmic staining. Figure B. Lung adenocarcinoma. The neoplastic cells of the adenocarcinoma show a strong cytoplasmic staining reaction. Figure C. Kidney. The proximal and distal tubules show a weak to strong distinct and predominantly membranous and cytoplasmic staining reaction. Figure D. Tonsil. The neutrophiles, eosinophiles and germinal center macrophages show a strong cytoplasmic staining reaction. 33 Antibody: Monoclonal Mouse Anti-Human CD19 Clone: LE-CD19 Code: IR656 or IS656 Clinical Application Reaction Location Recommended Control For identification of B cells in normal and neoplastic tissue (Fig. A and Fig. B). Membrane. Tonsil: Virtually all B cells both in the mantle zone and within the germinal centers should show a moderate to strong membranous staining reaction (Fig. C). No staining should be seen in the epithelial cells. Appendix/Colon: In the lamina propria, scattered plasma cells should show a weak to moderate membranous staining reaction (Fig. D). Differential Diagnosis* 1. B-cell lymphoma vs. T-cell lymphoma. 2. B-cell lymphoma relapse after MabThera (or similar anti-CD20) treatment. * Differential diagnosis is aided by the results from a panel of antibodies. 34 Figure A. Precursor B-cell lymphoblastic leukemia/lymphoma. The majority of the neoplastic cells show a moderate to strong predominantly membranous staining reaction. Figure B. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. The majority of the neoplastic cells show a moderate to strong predominantly membranous staining reaction. Figure C. Tonsil. The B cells in the mantle zone and in the germinal center show a moderate to strong membranous staining reaction. Figure D. Colon. The plasma cells in the lamina propria show a weak to moderate membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CD20cy Clone: L26 Code: IR604 or IS604 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of the B-cell lineage and different types of B-cell lymphoma (Fig. A) like mantle cell lymphoma (Fig. B). Membrane. Tonsil: Virtually all mantle zone and germinal center B cells should show a moderate to strong, crisp and continuous membranous staining reaction. The germinal center cells show a stronger staining reaction compared to mantle zone B cells (Fig. C). Scattered B cells in the squamous epithelial surface should show a weak to moderate staining reaction. The squamous epithelial cells should be negative. 1. Gastrointestinal lymphoma vs. carcinoma. 2. B-cell lymphoma vs. T-cell lymphoma. 3. Large B-cell lymphoma vs. melanoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. The majority of the neoplastic cells show a distinct membranous staining reaction. Figure B. Mantle cell lymphoma. The majority of the neoplastic cells show a distinct membranous staining reaction. Figure C. Tonsil. The mantle zone and germinal center B cells show a moderate to strong, crisp and continuous membrane staining reaction. 35 Antibody: Monoclonal Mouse Anti-Human CD21 Clone: 1F8 Code: IR608 or IS608 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of follicular dendritic cells, mature B cells and structural alterations in the meshwork of follicular dendritic cells in some malignant lymphomas like follicular lymphoma (Fig. A and Fig. B) and angioimmunoblastic T-cell lymphoma. Membrane. Tonsil: The follicular dendritic cells in the germinal centers should show a moderate to strong membranous staining reaction demonstrating the follicular dendritic network. In the mantle zone a few activated B cells may show a weak to moderate membranous staining reaction (Fig. C). 1. Follicular dendritic cell tumor vs. other spindle cell tumors. 2. Angioimmunoblastic T-cell lymphoma vs. other T-cell lymphomas. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Follicular lymphoma (grade I). The follicular dendritic cell network is distinctively stained. Figure C. Tonsil. The follicular dendritic cells in the germinal center show a moderate to strong staining reaction, and the activated B cells in the mantle zone show a weak to moderate membranous staining reaction. 36 Figure B. Follicular lymphoma (grade III). The follicular dendritic cell network is distinctively stained. Antibody: Monoclonal Mouse Anti-Human CD23 Clone: DAK-CD23 Code: IR781 or IS781 NEW Clinical Application Reaction Location For identification of both normal B lymphocytes and malignant lymphomas such as B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (Fig.A). Mantle cell lymphoma is generally negative for CD23 (Fig. B). Membrane. Recommended Control Tonsil: The follicular dendritic cells in the germinal centers should show a moderate to strong membranous staining reaction, and a subpopulation of B cells in the mantle zone should show a weak to moderate membranous staining reaction (Fig. C). Differential Diagnosis* B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma vs. mantle cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. The majority of the neoplastic cells show a distinct membranous staining reaction. Figure B. Mantle cell lymphoma. The neoplastic cells are negative and only remnants of entrapped follicular dendritic cells show a positive staining reaction. Figure C. Tonsil. Follicular dendritic cells in the germinal centers show a moderate to strong staining reaction, and a subpopulation of B cells in the mantle zone show a weak to moderate staining reaction. 37 Antibody: Monoclonal Mouse Anti-Human CD30 Clone: Ber-H2 Code: IR602 or IS602 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of Reed-Sternberg cells in Hodgkin lymphoma (Fig. A) and anaplastic large cell lymphoma (Fig. B). Membrane and cytoplasm (paranucleus). Tonsil: At the edge of the germinal centers, a few activated cells should show a moderate to strong membranous staining reaction with a focal paranuclear dot-like staining. Plasma cells may show a focal cytoplasmic staining reaction (Fig. C). 1. Hodgkin lymphoma vs. thymoma. 2. Hodgkin lymphoma vs. T-cell-rich B-cell lymphoma. 3. Embryonal carcinoma vs. testicular seminoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Classic Hodgkin lymphoma. The majority of the Reed-Sternberg cells show a distinct membranous staining reaction and a paranuclear dot-like reaction. Figure C. Tonsil. Activated lymphocytes and plasma cells show a moderate to strong staining reaction. 38 Figure B. Anaplastic large cell lymphoma. The majority of the neoplastic cells show a distinct membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CD31, Endothelial Cell Clone: JC70A Code: IR610 or IS610 Clinical Application Reaction Location Recommended Control For identification of endothelial cells, and benign and malignant vascular disorders such as hemangiosarcoma (Fig. A), kaposi sarcoma (Fig. B) and angiosarcomas. Membrane and cytoplasm. Appendix/Colon: A moderate to strong and predominantly membranous, but also cytoplasmic staining reaction should be seen in the normal blood and lymphatic vascular endothelial cells (Fig. C). Activated B and T cells should show a weak to moderate staining reaction. Tonsil: Endothelial cells in vascular and lymphatic spaces should show a moderate to strong cytoplasmic staining reaction, while the mantle zone B cells should show a weak to moderate membranous staining reaction (Fig. D). Differential Diagnosis* 1. Hemangiosarcoma vs. hemangiopericytoma. 2. Hemangioma vs. adenomatoid tumor. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Hemangiosarcoma. The majority of the neoplastic cells show a distinct membranous and cytoplasmic staining reaction. Normal blood vessel endothelium and lymphatic endothelium are strongly stained. Figure B. Kaposi sarcoma. An intense membranous and cytoplasmic staining is seen predominantly in the angiomatoid areas. Figure C. Colon. The normal blood and lymphatic vascular endothelial cells show a moderate to strong staining reaction. Figure D. Tonsil. The mantle zone B cells show a weak to moderate membranous staining reaction. 39 Antibody: Monoclonal Mouse Anti-Human CD34 Class II Clone: QBEnd 10 Code: IR632 or IS632 Clinical Application Reaction Location Recommended Control For identification of vascular and lymphatic vessels (Fig. A) and tumors of vascular origin (Fig. B). Membrane. Appendix: The endothelial cells of all vessels should show a distinct predominantly membranous staining reaction. Especially, the endothelial cells of the small submucosal vessels should be demonstrated. Lymphoid and epithelial cells should be negative, focally, stromal cells can be positive. Liver: The endothelial cells of the portal vessels and the periportal sinusoids should show a distinct moderate to strong staining reaction. Hepatocytes should be negative (Fig. C). Differential Diagnosis* 1. Dermatofibrosarcoma vs. dermatofibroma. 2. Solitary fibrous tumor vs. sarcomatoid mesothelioma. 3. Gastrointestinal stromal tumor vs. gastrointestinal carcinoma. 4. Malignant phyllode tumors vs. spindle cell carcinoma of the breast. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Lymphoma. The endothelial cells of vascular and lymphatic vessels show a strong predominantly membranous staining reaction. Figure C. Liver. The endothelial cells of the portal vessels and the periportal sinusoids show a moderate to strong distinct staining reaction. 40 Figure B. Angiosarcoma. The neoplastic cells show a moderate to strong and predominantly membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CD43 Clone: DF-T1 Code: IR636 or IS636 Clinical Application Reaction Location Recommended Control For identification of low-grade B-cell lymphoma (Fig. A), peripheral T-cell lymphoma (Fig. B) and myeloid disorders. Membrane. Tonsil: Virtually all T cells should show a predominantly membranous staining reaction. The crowded T cells in the T-zone should show a strong staining reaction. The scattered T cells and macrophages in the germinal center should show a moderate to strong staining reaction (Fig. C). Appendix/Colon: The T cells and plasma cells in lamina propria should show a moderate to strong membranous staining reaction. The macrophages should show a weak to moderate staining reaction, while the epithelial cells should be negative (Fig. D). Differential Diagnosis* 1. Mantle cell lymphoma/B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma vs. follicular lymphoma. 2. Reactive B cells vs. neoplastic B cells. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. The neoplastic cells show a moderate distinct staining reaction, and normal T cells show a strong distinct staining reaction. Figure B. Peripheral T-cell lymphoma. The majority of the neoplastic cells show a distinct membranous staining reaction. Figure C. Tonsil. The crowded T cells in the T-zone show a strong staining reaction, whereas the scattered T cells and macrophages in the germinal center show a moderate to strong staining reaction. Figure D. Appendix. The T cells and plasma cells in lamina propria show a moderate to strong staining reaction, and the macrophages show a weak to moderate staining reaction. 41 Antibody: Monoclonal Mouse Anti-Human CD45, Leucocyte Common Antigen Clone: 2B11 + PD7/26 Code: IR751 or IS751 Clinical Application Reaction Location Recommended Control For identifying tumors of lymphoid origin (Fig. A and Fig. B). Membrane. Tonsil: All lymphocytes should show a moderate to strong membranous staining reaction. Histiocytes and macrophages should at least show a weak membranous staining reaction. Surface epithelial cells should be negative (Fig. C). Brain: The microglial cells should show a weak to moderate and predominantly membranous staining reaction (Fig. D). Bone marrow: All lymphoid cells should be strongly stained in a crisp cell membrane pattern. Differential Diagnosis* 1. Lymphoma vs. seminoma. 2. Lymphoma vs. carcinoma. 3. Lymphoma vs. sarcoma. 4. Lymphoma vs. melanoma. * Differential diagnosis is aided by the results from a panel of antibodies. 42 Figure A. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. The majority of the neoplastic cells show a strong membranous staining reaction. Figure B. Acute myeloid leukemia. The neoplastic cells show a strong membranous staining reaction. Figure C. Tonsil. Lymphocytes show a strong membranous staining reaction, whereas histiocytes and macrophages show a weak to moderate membranous staining reaction. Figure D. Cerebellum. The microglial cells show a weak to moderate and predominantly membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CD56 Clone: 123C3 Code: IR628 or IS628 Clinical Application Reaction Location Recommended Control For identification of natural killer (NK) cells, NK-like T cells, neural/neuroendocrine tissues and their neoplasms such as small cell carcinoma of the lung (Fig. A) and carcinoid tumor (Fig. B). Membrane. Colon: A moderate to strong and predominantly membranous staining reaction should be seen in the peripheral nerves in tunica muscularis - both the axons and the ganglion cells should be stained (Fig. C). Tonsil: The NK cells should show a weak to moderate membranous staining reaction (Fig. D). Differential Diagnosis* Small cell carcinoma of lung vs. Ewing’s sarcoma/primitive neuroectodesmal tumor. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Small cell carcinoma of the lung. The majority of the neoplastic cells show a strong predominantly membranous staining reaction. Figure B. Carcinoid tumor. The majority of the neoplastic cells show a predominantly membranous staining reaction. Figure C. Colon. The peripheral nerves in tunica muscularis - both the axons and the ganglion cells – show a moderate to strong and predominantly membranous staining reaction. Figure D. Tonsil. The NK cells show a weak to moderate membranous staining reaction. 43 Antibody: Monoclonal Mouse Anti-Human CD57 Clone: TB01 Code: IR647 or IS647 Clinical Application Reaction Location Recommended Control For identification of Hodgkin lymphoma (lymphocyte-predominant subtype) (Fig. A and Fig. B), T-cell large granular lymphocyte disorder, oligodendroglioma and neuroendocrine tumor. Membrane and/or cytoplasmic. Tonsil: Scattered activated T cells predominantly located in the germinal center as well as NK cells in the T-zone of the tonsil and at the edge of the germinal center should show a moderate to strong staining reaction (Fig. C). Appendix/Colon: Schwann cells of the post-ganglionic neurons and their cell bodies should show a weak to moderate staining reaction (Fig. D). Neuroendocrine cells in the epithelial surface should show a distinct staining reaction, whereas the epithelial cells should be negative. Differential Diagnosis* T-cell large granular lymphocyte disorders vs. malignant fibrous histiocytoma and fibrosarcoma. * Differential diagnosis is aided by the results from a panel of antibodies. 44 Figure A. Hodgkin lymphoma (LP subtype). T cells surrounding the L&H cells show a distinct membranous staining reaction. Figure B. Hodgkin lymphoma (LP subtype). T cells surrounding the L&H cells show a distinct membranous staining reaction. Figure C. Tonsil. Scattered activated T cells as well as NK cells located in the germinal center show a moderate to strong staining reaction. Figure D. Appendix. Schwann cells of the post-ganglionic neurons and their cell bodies show a weak to moderate staining reaction. The neuroendocrine cells in the epithelial surface show a strong staining reaction, whereas the epithelial cells are negative. Antibody: Monoclonal Mouse Anti-Human CD68 Clone: KP1 Code: IR609 or IS609 Clinical Application Reaction Location Recommended Control For identification of macrophages, other members of the mononuclear phagocyte lineage, and neoplasm of myeloid (Fig. A and Fig. B) and macrophage/monocyte origin. Cytoplasm. Tonsil: In the germinal centers of the secondary follicles, the macrophages should show a moderate to strong cytoplasmic staining reaction. In the interfollicular areas, the granulocytes and macrophages should show a granular cytoplasmic staining reaction (Fig. C). Normal brain: The microglial cells should show a weak to moderate cytoplasmic staining reaction while the other cell types should be negative (Fig. D). Differential Diagnosis* 1. Histiocytosis vs. T-cell lymphoma. 2. Myeloid neoplasms vs. lymphoid neoplasms. 3. Acute myeloid leukemia vs. acute lymphoblastic leukemia. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Acute myeloid leukemia (FAB type M1). The neoplastic cells show a distinct granular cytoplasmic staining reaction. Figure B. Acute myeloid leukemia (FAB type M5). The neoplastic cells show a distinct granular cytoplasmic staining reaction. Figure C.Tonsil. In the germinal center, the macrophages show a moderate to strong cytoplasmic staining reaction. Figure D. Cerebellum. The microglial cells show a weak to moderate cytoplasmic staining reaction, while the other cell types are negative. 45 Antibody: Monoclonal Mouse Anti-Human CD68 Clone: PG-M1 Code: IR613 or IS613 Clinical Application Reaction Location Recommended Control For identification of macrophages, M4 (myelomonocytic) and M5 (monocytic) types of acute myeloid leukemia (Fig. A and Fig. B), and histiocytic sarcoma. Acute myeloid leukemia (FAB type M1) is negative for this protein. Cytoplasm. Tonsil: In the germinal centers of the secondary follicles, the macrophages should show a moderate to strong cytoplasmic staining reaction. In the interfollicular areas, the granulocytes and macrophages should show a granular cytoplasmic staining reaction (Fig. C). Normal brain: The microglial cells should show a weak to moderate cytoplasmic staining reaction, while the other cell types should be negative (Fig. D). Differential Diagnosis* 1. Acute myeloid leukemia (FAB type M4 and M5) vs. acute myeloid leukemia (FAB type M1, M2 and M3). 2. Histiocytosis vs. T-cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. 46 Figure A. Acute myeloid leukemia (FAB type M1). The neoplastic cells of subtype M1 are negative (expect a few normal myelocytes). Monocytes and cells with monocytic differentiation show a cytoplasmic staining reaction. Figure B. Acute myeloid leukemia (FAB type M5). The neoplastic cells of subtype M5 show a distinct cytoplasmic staining reaction. Monocytes and cells with monocytic differentiation show a cytoplasmic staining reaction. Figure C. Tonsil. In the germinal center, the macrophages show a moderate to strong cytoplasmic staining reaction. Figure D. Cerebellum. The microglial cells show a weak to moderate cytoplasmic staining reaction, while the other cell types are negative. Antibody: Monoclonal Mouse Anti-Human CD79a Clone: JCB117 Code: IR621 or IS621 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of B cells during all stages of differentiation and of B-cell neoplasm (Fig. A and Fig. B). Cytoplasm and membrane. Tonsil: The mantle zone B cells should show a moderate to strong membranous and cytoplasmic staining reaction, while the germinal center B cells should show a moderate, but distinct staining reaction. Plasma cells should show a strong cytoplasmic staining reaction (Fig. C). B-cell lymphoma vs. T-cell lymphoma, except for T-lymphoblastic lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Plasmacytoma. The majority of the neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure B. Precursor B-lymphoblastic leukemia/lymphoma disseminated to the testis. The majority of the neoplastic cells show a weak to moderate staining reaction. Figure C. Tonsil. The mantle zone B cells show a strong staining reaction, while the germinal center B cells show a moderate staining reaction. Plasma cells show a strong cytoplasmic staining reaction. 47 Antibody: Monoclonal Mouse Anti-Human CD99, MIC2 Gene Products, Ewing’s Sarcoma Marker Clone: 12E7 Code: IR057 or IS057 Clinical Application Reaction Location Recommended Control For identification of glioblastomas and ependymomas of the CNS, certain islet cell tumors of the pancreas, Ewing’s sarcoma (Fig. A), granulosa cell tumor (Fig. B) and primitive peripheral neuroectodermal tumors. Membrane and cytoplasm. Pancreas: Islet cells should show a moderate to strong cytoplasmic staining reaction (Fig. C). Tonsil: The lymphocytes should a show a weak to moderate and predominantly membranous staining reaction. The squamous epithelial cells should show a weak to moderate membranous staining reaction (Fig. D). Thymus: A moderate to strong membranous staining reaction should be seen in the cortical thymocytes. Differential Diagnosis* * Differential diagnosis is aided by the results from a panel of antibodies. 48 1. Synovial sarcoma vs. spindle cell carcinoma vs. sarcomatoid mesothelioma vs. biphasic mesothelioma. 2. Ewing’s sarcoma/primitive neuroectodesmal vs. small cell carcinoma. 3. Ewing’s sarcoma/primitive neuroectodesmal vs. rhabdomyosarcoma. 4. Granulosa cell tumor vs. carcinoma. Figure A. Ewing’s sarcoma. Most tumor cells show a strong membranous and cytoplasmic staining reaction. Figure B. Granulosa cell tumor. The neoplastic cells show a weak to moderate membranous and cytoplasmic staining reaction. Figure C. Pancreas. The pancreatic islet cells show a moderate to strong cytoplasmic staining reaction. Figure D. Tonsil. The squamous epithelial cells show a weak to moderate membranous staining reaction. Antibody: Monoclonal Mouse Anti-Human CD138 Clone: MI15 Code: IR642 or IS642 Clinical Application Reaction Location Recommended Control For identification of malignancies involving terminally differentiated plasma cells and multiple myeloma (Fig. A), and for subclassification of diffuse large B-cell lymphoma (Fig. B). Membrane. Tonsil: The majority of the plasma cells should show a moderate to strong predominantly membranous staining reaction. In the germinal center, scattered stimulated immunoblasts should show a weak to moderate staining reaction, while the majority of the germinal center cells and peripheral lymphocytes should be negative. The epithelial cells should show a weak to moderate staining reaction (Fig. C). Appendix/Colon: The majority of the plasma cells in lamina propria should show a moderate to strong membranous staining reaction. The luminal and basal epithelial cells should be demonstrated (Fig D). Differential Diagnosis* 1. Subtyping of diffuse large B-cell lymphoma. 2. Carcinoma vs. mesothelioma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Myeloma. The majority of the neoplastic cells show a strong and distinct membranous staining reaction. Figure B. Diffuse large B-cell lymphoma. The neoplastic cells show a distinct membranous staining reaction. Figure C. Tonsil. The majority of the plasma cells show a moderate to strong predominantly membranous staining reaction. In the germinal center, scattered stimulated immunoblasts show a moderate to strong staining reaction. The epithelial cells show a moderate staining reaction. Figure D. Appendix. The plasma cells in lamina propria and the epithelial cells show a moderate to strong predominantly membranous staining reaction. 49 Antibody: Monoclonal Mouse Anti-Human CD246, ALK Protein Clone: ALK1 Code: IR641 or IS641 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of ALK-positive anaplastic large cell lymphoma (Fig. A and Fig. B). Nucleus and/or cytoplasm. Anaplastic large cell lymphoma (t (2;5) translocation): Scattered neoplastic cells should show a strong nuclear and cytoplasmic staining reaction (Fig. A and Fig. B). ALK-positive anaplastic large cell lymphomas vs. classical Hodgkin lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Anaplastic large cell lymphoma (t(2;5) translocation). Scattered neoplastic cells show a strong nuclear and cytoplasmic staining reaction. 50 Figure B. Anaplastic large cell lymphoma (t(2;5) translocation). Scattered neoplastic cells show a strong nuclear and cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human CDX-2 Clone: DAK-CDX-2 Code: IR080 or IS080 Clinical Application Reaction Location Recommended Control For identification of adenocarcinoma (Fig. A) and carcinoids (Fig. B) of the gastrointestinal tract. Nucleus. Appendix: Virtually all the enterocytes of the appendiceal mucosa should show a moderate to strong nuclear reaction (Fig. C). The basal cells should show a strong staining reaction, whereas the luminal cells should show a moderate staining reaction. The cytoplasmic compartment should be negative or show only a weak staining reaction. Pancreas: The ductal and scattered intercalated/central acinar epithelial cells should show a distinct weak to moderate nuclear staining reaction (Fig. D). No cytoplasmic staining reaction should be seen. Differential Diagnosis* Metastatic adenocarcinoma of the intestinal tract vs. other organs. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma. The neoplastic cells show a strong nuclear staining reaction. Figure B. Carcinoids. The tumor cells of a gastrointestinal carcinoid tumor show a strong nuclear staining reaction. Figure C. Appendix. Mucosal epithelial cells show a strong nuclear staining reaction. Figure D. Pancreas. The intercalated epithelial cells show a weak to moderate nuclear staining reaction. 51 Antibody: Polyclonal Rabbit Anti-Human Chorionic Gonadotropin Code: IR508 or IS508 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of human chorionic gonadotropin-containing trophoblastic elements in germ cell tumors, choriocarcinoma (Fig. A), granulosa cell tumor, hydatiform mole and seminoma with syncytiotrophoblastic giant cells (Fig. B). Cytoplasm. Placenta: The syncytiotrophoblasts and trophoblasts should show a moderate to strong and distinct predominantly cytoplasmic reaction. The stroma should be negative, and only a weak reaction should be seen in macrophages and serum (Fig. C). 1. Choriocarcinoma vs. epithelial trophoblastic tumors. 2. Testicular seminoma vs. embryonal carcinoma. 3. Complete hydatidiform mole vs. partial hydatidiform mole. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Chorionic carcinoma. The neoplastic syncytiotrophoblasts show a moderate to strong cytoplasmic staining reaction with minimal background staining. Figure C. Placenta.The trophoblasts and syncytiotrophoblasts show a strong and distinct predominantly cytoplasmic staining reaction. 52 Figure B. Seminoma. The neoplastic syncytiotrophoblast cells show a moderate to strong cytoplasmic staining reaction. Antibody: Polyclonal Rabbit Anti-Human Chromogranin A Code: IR502 or IS502 Clinical Application Reaction Location Recommended Control For identification of neuroendocrine cells and tumors with neuroendocrine differentiation. For example, small cell lung carcinoma (Fig. A), medullary carcinoma of thyroid (Fig. B), parathyroid tumors, paraganglioma and carcinoid tumors are positive for this antibody. Cytoplasm. Appendix/Colon: The neuroendocrine cells in the epithelial surface should show a moderate to strong coarse cytoplasmic staining reaction, whereas the epithelial cells should be negative. The axons and perikarya of the neurons and ganglion cells in the submucosa and in the tunica muscularis (Auerbach’s plexus) should show a weak to moderate granular cytoplasmic staining reaction and no staining of the surrounding muscle cells (Fig. C and D). Brain: The cortical neurons and axons should show a distinct granular staining reaction. Differential Diagnosis* 1. Pheochromocytoma vs. adrenocortical tumor. 2. Carcinoids vs. carcinoma. 3. Thyroid medullary carcinoma vs. thyroid follicular carcinoma. 4. Islet cell tumor vs. acinic cell carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Small cell lung carcinoma. The majority of the neoplastic cells show a finely granular, distinct cytoplasmic and focally dot-like staining reaction. Figure B. Medullary thyroid carcinoma. The majority of the neoplastic cells show a distinct cytoplasmic staining reaction. Figure C. Colon. The neuroendocrine cells in the epithelial surface show a moderate to strong coarse cytoplasmic staining reaction, whereas the epithelial cells are negative. Figure D. Colon. The axons and perikarya of the neurons and ganglion cells in the submucosa and in the tunica muscularis show a weak to moderate granular cytoplasmic staining reaction 53 Antibody: Monoclonal Rabbit Anti-Human Cyclin D1 Clone: EP12 Code: IR083 or IS083 NEW Clinical Application Reaction Location For identification of mantle cell lymphoma (Fig. A). Most B-cell chronic lymphocytic leukemia/ small lymphocytic lymphomas should be negative. Nucleus. Recommended Control Tonsil: The suprabasel layer of the squamous epithelium should show a moderate to strong nuclear staining reaction (Fig. B), while the lymphoid tissue should show no staining reaction. Differential Diagnosis* Mantle cell lymphoma vs. chronic lymphocytic leukemia/lymphoma and follicular lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Mantle cell lymphoma. The neoplastic cells show a moderate to strong nuclear staining reaction. 54 Figure B. Tonsil. The suprabasel layer of the squamous epithelium shows a moderate to strong staining reaction. Antibody: Monoclonal Mouse Anti-Human Cytokeratin Clone: AE1/AE3 Code: IR053 or IS053 Clinical Application Reaction Location Recommended Control For identification of tumors of epithelial origin such as squamous cell carcinoma, seminoma (Fig. A) and Merkel cell tumor (Fig. B). Cytoplasm. Tonsil: The squamous mucosa should show a strong and diffuse cytoplasmic staining reaction in all cell layers. The interdigitating reticulum cells of the lymphoid tissue can be positive (Fig. C). Liver: The majority of the hepatocytes should show a weak to moderate and predominantly membranous reaction, and the bile duct epithelial cells should show a moderate to strong cytoplasmic staining reaction (Fig.D). Differential Diagnosis* 1. Carcinoma vs. sarcoma. 2. Carcinoma vs. melanoma. 3. Carcinoma vs. lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Seminoma. Focally, some neoplastic cells show a moderate cytoplasmic staining reaction, while the vast majorities are entirely negative. Figure B. Merkel cell tumor. Some neoplastic cells show a focal and dotlike cytoplasmic staining reaction for cytokeratin. Figure C. Tonsil. The squamous mucosa show a strong and diffuse cytoplasmic staining reaction in all cell layers. Figure D. Liver. The majority of the liver cells show a moderate predominantly membranous staining reaction, and the bile duct epithelial cells show a strong cytoplasmic staining reaction. 55 Antibody: Monoclonal Mouse Anti-Human Cytokeratin 5/6 Clone: D5/16 B4 Code: IR780 or IS780 Clinical Application Reaction Location Recommended Control For differential diagnosis of poorly differentiated squamous cell carcinoma (Fig. A) vs. adenocarcinoma, epithelioid mesothelioma vs. lung carcinoma, usual/atypical ductal hyperplasia vs. ductal carcinoma in situ of the breast, and prostate carcinoma vs. its benign mimics (Fig. B). Cytoplasm. Tonsil: The squamous epithelial cells should show a moderate to strong cytoplasmic staining reaction. The staining should be seen in all cell layers in the epithelial surface (Fig. C). Prostate: The basal cells should show a weak to moderate cytoplasmic staining reaction with no or only focal staining of the secretory cells (Fig. D). Differential Diagnosis* 1. Mesothelioma vs. adenocarcinoma. 2. Benign prostatic glands vs. prostatic adenocarcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. 56 Figure A. Squamous cell carcinoma of lung. The majority of the neoplastic cells show a strong cytoplasmic staining reaction. Figure B. Prostate hyperplasia and prostate carcinoma. The normal and benign glands show a distinct cytoplasmic staining reaction in the basal cells. Normal secretory cells and the neoplastic cells are negative or show only a focal staining reaction. Figure C. Tonsil. The squamous epithelial cells show a moderate to strong cytoplasmic staining reaction. The staining reaction is seen in all cell layers. Figure D. Prostate. The basal cells show a moderate cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Cytokeratin 7 Clone: OV-TL12/30 Code: IR619 or IS619 Clinical Application Reaction Location Recommended Control For identification of tumors of unknown origins and for staining of cytokeratin 7 (CK 7) in glandular and transitional epithelial cells appearing in various tumors such as adenocarcinoma of the lung, breast (Fig. A), endometrium, thyroid gland, ovary (Fig. B) and chromophobe renal cell carcinoma. Cytoplasm. Pancreas: The epithelial cells of the large, intermediate and intercalating ducts should show a distinct cytoplasmic staining reaction. The epithelial cells of the large acinar ducts should show a moderate to strong staining reaction, whereas the epithelial cells of the intercalating pancreatic ducts should show a weak to moderate staining reaction. The pancreatic acinar cells should be negative (Fig. C). Breast: The breast epithelial cells should show a strong cytoplasmic staining reaction. Differential Diagnosis* * Differential diagnosis is aided by the results from a panel of antibodies. 1. Carcinoma of the urinary bladder vs. prostatic carcinoma. 2. Ovarian carcinoma vs. colonic carcinoma. 3. Lung carcinoma vs. breast carcinoma. 4. Cholangiocarcinoma vs. hepatoma. 5. Paget’s disease vs. Bowen’s disease. Figure A. Breast lobular carcinoma. The majority of the neoplastic cells show a distinct and predominantly cytoplasmic, but also membrane accentuated staining reaction. Figure C. Pancreas. The epithelial cells of the large acinar ducts show a moderate to strong staining reaction, whereas the epithelial cells of the intercalating pancreatic ducts show a weak to moderate staining reaction. The pancreatic acinar cells are negative. Figure B. Serous ovarian carcinoma. A strong cytoplasmic staining reaction is seen in the neoplastic cells. 57 Antibody: Monoclonal Mouse AntiCytokeratin 17 Clone: E3 Code: IR620 or IS620 Clinical Application Reaction Location Recommended Control For staining of cytokeratin (CK 17) in myoepithelial cells of human complex epithelia found in various carcinomas such as pancreatic adenocarcinoma (Fig. A) and squamous cell carcinoma of the lung (Fig. B). Membrane and cytoplasm. Skin: A moderate to strong cytoplasmic staining reaction should be seen in the squamous, granular and cornified layer of the hair follicles, whereas the basal layer should be negative. The apocrine glands should be at least focally stained in cytoplasm/membrane. Myoepithelial cells (Fig. C) of the sweat glands should show a moderate to strong cytoplasmic staining reaction. The normal gland epithelial cells and the squamous epithelium should be negative. Breast hyperplasia: The myoepithelial cells of the epithelial acini should show a strong and distinct cytoplasmic staining reaction with no staining in the epithelial cells. Differential Diagnosis* Pancreatic adenocarcinoma vs. gastric adenocarcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Pancreatic adenocarcinoma. A moderate to strong cytoplasmic staining reaction is seen in a large proportion of the neoplastic cells. Figure C. Skin. The myoepithelial cells of the sweat glands show a moderate to strong cytoplasmic staining reaction. 58 Figure B. Lung squamous cell carcinoma. The neoplastic cells show a moderate to strong membranous and cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Cytokeratin 18 Clone: DC 10 Code: IR618 or IS618 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of some epithelial tumors like Merkel cell carcinoma (Fig. A), seminoma (Fig. B) and epithelioid hemangioendothelioma. Membrane and cytoplasm. Liver: The bile duct epithelial cells should show a moderate to strong cytoplasmic staining reaction, whereas the liver cells should show a weak to moderate and predominantly membranous staining reaction. The staining reaction can be heterogeneous with the strongest staining in the periportal zones. Kupffer cells should be negative (Fig. C). 1. Merkel cell carcinoma vs. basal cell carcinoma. 2. Seminoma vs. melanoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Merkel cell carcinoma. The majority of the neoplastic cells show a distinct cytoplasmic and focally dot-like staining reaction. Figure B. Seminoma. Several neoplastic cells show a focal and distinct cytoplasmic staining reaction - in some areas the staining may be more dot-like. The majority of the neoplastic cells are negative. Figure C. Liver. The bile duct epithelial cells show a moderate to strong cytoplasmic staining reaction, whereas the liver cells show a weak to moderate staining reaction. 59 Antibody: Monoclonal Mouse Anti-Human Cytokeratin 19 Clone: RCK108 Code: IR615 or IS615 Clinical Application Reaction Location Recommended Control For identification of epithelial tumors with cytokeration 19 (CK 19)-expression such as breast carcinoma (Fig. A), thyroid papillary carcinoma (Fig. B) and cholangiocarcinoma. Cytoplasm. Liver: The bile duct epithelial cells should show a moderate to strong cytoplasmic staining reaction, whereas the liver cells should be negative (Fig. C). Tonsil: The squamous epithelial cells should focally show a weak to moderate cytoplasmic staining reaction with the strongest staining in the basal layer (Fig. D). Esophageal or vaginal mucosa: The basal cells of the mucosa should show a strong cytoplasmic staining reaction. Differential Diagnosis* 1. Cholangiocarcinoma vs. hepatocellular carcinoma. 2. Thyroid papillary carcinoma vs. hyalinizing trabecular tumor of thyroid. * Differential diagnosis is aided by the results from a panel of antibodies. 60 Figure A. Breast carcinoma. The majority of the neoplastic cells show a strong cytoplasmic staining reaction. Figure B. Thyroid papillary carcinoma. The neoplastic cells show a strong cytoplasmic staining reaction, whereas the adjacent normal thyroid is negative. Figure C. Liver. The bile duct epithelial cells show a moderate to strong cytoplasmic staining reaction, whereas the liver cells are negative. Figure D. Tonsil. Focally, the squamous epithelial cells show a weak to moderate cytoplasmic staining reaction with the strongest staining in the basal layer. Antibody: Monoclonal Mouse Anti-Human Cytokeratin 20 Clone: Ks20.8 Code: IR777 or IS777 Clinical Application Reaction Location Recommended Control Differential Diagnosis* Primarily for identification of gastrointestinal tumors (Fig. A), mucinous ovarian tumors and Merkel cell carcinoma (Fig. B). Anti-Cytokeratin 20 stains the normal gastrointestinal epithelium and urothelium. Cytoplasm. Appendix/Colon: The columnar epithelial cells should show a distinct cytoplasmic staining reaction. The luminal cells will typically show a moderate to strong staining reaction, whereas the epithelial cells of the basal crypts will only show a weak to moderate staining reaction, except for endocrine cells that should show a moderate to strong staining reaction (Fig. C). 1. Merkel cell carcinoma vs. basal cell carcinoma. 2. Colonic carcinoma vs. ovarian carcinoma vs. colon carcinoid. 3. Cholangiocarcinoma vs. hepatoma vs. fibrolamellar hepatoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma. The majority of the neoplastic cells show a strong cytoplasmic staining reaction. Figure C. Colon. The luminal cells show a moderate to strong staining reaction, whereas the epithelial cells of the basal crypts show a weak to moderate staining reaction. Endocrine cells of the basal crypt show a moderate to strong staining reaction. Figure B. Merkel cell carcinoma. The majority of the neoplastic cells show a perinuclear cytoplasmic and dot-like staining reaction. 61 Antibody: Monoclonal Mouse Anti-Human Cytokeratin, High Molecular Weight Clone: 34βE12 Code: IR051 or IS051 Clinical Application Reaction Location Recommended Control For differential diagnosis between prostatic adenocarcinoma and prostatic intraepithelial neoplasia (PIN) or its benign mimics such as atypical hyperplasia. The demonstration of cytokeratin high molecular weight (CK HMW) in the basal cells is indicative of benign lesion, whereas the absence is indicative of malignancy (Fig. A and Fig. B). Anti-CK HMW should be used with antibodies to other markers such as AMACR for a more precise diagnosis. AntiCK HMW is also used in the demonstration of squamous cell carcinoma of lung, epithelioid mesothelioma, transitional cell carcinoma and nasopharyngeal carcinoma. Cytoplasm. Tonsil: The squamous epithelial cells should show a moderate to strong distinct cytoplasmic staining reaction. The staining reaction should be seen in all cell layers in the epithelial surface (Fig. C). Prostate: The basal cells should show a strong cytoplasmic staining reaction with no or only focal reaction of the secretory cells. Differential Diagnosis* 1. Prostatic intraepithelial neoplasia vs. prostatic adenocarcinoma. 2. Breast ductal adenosis vs. breast tubular carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Prostate adenocarcinoma. The basal cells show a strong cytoplasmic staining reaction with a continuous pattern in a normal gland (center). The staining reaction is absent in the adjacent carcinoma cells. Figure C.Tonsil. The squamous epithelial cells show a strong distinct cytoplasmic staining reaction. 62 Figure B. Prostate adenocarcinoma. Various staining reaction patterns are seen: Continuous cytoplasmic staining in normal gland, discontinuous pattern in PIN and no staining in invasive cancer cells. Antibody: Monoclonal Mouse AntiCytomegalovirus Clone: CCH2 + DDG9 Code: IR752 or IS752 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of cytomegalovirus infection in human tissues (Fig. A and Fig. B). Nucleus and cytoplasm. Lesion with cytomegalovirus infection: Cells infected with cytomegalovirus should show a moderate to strong nuclear and cytoplasmic staining reaction (Fig. A and Fig. B). No background staining should be seen. Cytomelogavirus infection vs. other infections. * Differential diagnosis is aided by the results from a panel of antibodies.  Not available in the US. Figure A. Lung tissue with cytomegalovirus infection. The lung lesion shows a strong nuclear and cytoplasmic staining reaction of cytomegalovirus. Figure B. Lung tissue with cytomegalovirus infection. Infected cells show a strong nuclear and cytoplasmic staining reaction of cytomegalovirus in the alveoli. 63 Antibody: Monoclonal Mouse Anti-Human D2-40 Clone: D2-40 Code: IR072 or IS072 Clinical Application Reaction Location Recommended Control For identification of lymphatic invasion in a variety of cancers and the differential diagnosis between epithelioid mesothelioma (Fig. A) and lung adenocarcinoma. Seminoma often shows a positive staining reaction (Fig. B). Cytoplasm and membrane Appendix: The lymphatic endothelial cells should show a moderate to strong predominantly cytoplasmic staining reaction and the Cajal cells of the muscularis propria should show a weak to moderate predominantly membranous staining reaction (Fig. C). Endothelial cells should be negative. Tonsil: The lymphatic endothelial cells, follicular dendritic cells and basal squamous endothelial cells should show a moderate to strong staining reaction (Fig. D). Differential Diagnosis* 1. Mesothelioma vs. adenocarcinoma. 2. Lymphatic endothelium vs. blood vessel endothelium. * Differential diagnosis is aided by the results from a panel of antibodies. 64 Figure A. Mesothelioma. The majority of the neoplastic cells show a moderate to strong membranous and cytoplasmic staining reaction. Figure B. Seminoma. The neoplastic cells and lymphatic endothelial cells show a strong membranous and cytoplasmic staining reaction. Figure C. Appendix. Cajal cells (lower left corner) show a moderate to strong cytoplasmic staining reaction. Figure D. Tonsil. The lymphatic endothelial cells and basal epithelial cells show a moderate to strong cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Desmin Clone: D33 Code: IR606 or IS606 Clinical Application Reaction Location Recommended Control For identification of smooth and striated muscle cells and reactive mesothelial cells, tumors of muscle origin like leiomyoma (Fig. A) and rhabdomyosarcoma (Fig. B). Cytoplasm. Appendix/Colon: The smooth muscle cells in muscularis mucosa and muscularis propria as well as along the crypts in lamina propria should show a moderate to strong cytoplasmic staining reaction. In lamina propria, the majority of the smooth muscle cells in the small vessels should show a weak to moderate occasionally dot-like staining reaction (Fig. C). Striated muscle: An intense cytoplasmic staining reaction concentrated in the Z-bands should be seen in the muscle cells. Differential Diagnosis* 1. Sarcoma vs. lymphoma. 2. Sarcoma vs. carcinoma vs. malignant mesothelioma. 3. Sarcoma vs. melanoma. 4. Rhabdomyosarcoma vs. Ewing’s sarcoma/primitive neuroectodesmal tumor. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Uterine leiomyoma. The majority of the neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure C. Colon. The smooth muscle cells along the crypts in lamina propria show a moderate to strong cytoplasmic staining reaction. The smooth muscle cells in the small vessels show a weak to moderate staining reaction. Figure B. Rhabdomyosarcoma. The majority of the neoplastic cells show a moderate to strong cytoplasmic staining reaction. 65 Antibody: Monoclonal Mouse Anti-Human E-Cadherin Clone: NCH-38 Code: IR059 or IS059 Clinical Application Reaction Location Recommended Control For differential diagnosis between ductal and lobular carcinoma of the breast. E-cadherin is positive in breast ductal carcinoma (Fig. A) and negative in lobular carcinoma (Fig. B). E-cadherin also stains normal breast duct and various tumors such as esophageal adenocarcinoma and squamous carcinoma, and transitional cell carcinoma of the bladder. Membrane. Appendix/Colon: Virtually all the epithelial cells should show a moderate to strong distinct membranous staining reaction (Fig. C). Liver: Both the hepatocytes and the ductal cells should show a weak to moderate distinct membranous staining reaction (Fig. D). Differential Diagnosis* Breast ductal carcinoma vs. breast lobular carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. 66 Figure A. Breast ductal carcinoma. All the tumor cells show a strong membranous staining reaction. Figure B. Breast lobular carcinoma. The breast lobular carcinoma cells stain negative. Figure C. Appendix. Virtually all the epithelial cells show a strong membranous staining reaction. Figure D. Liver. The hepatocytes show a weak to moderate staining reaction. Antibody: Monoclonal Mouse Anti-Human Epithelial Antigen Clone: Ber-EP4 Code: IR637 or IS637 Clinical Application Reaction Location Recommended Control For differential diagnosis of adenocarcinoma (Fig. A) vs. malignant mesothelioma (Fig B.) and basal cell carcinoma vs. squamous cell carcinoma of the skin. Membrane and cytoplasm. Appendix/Colon: The epithelial cells should show a moderate to strong predominantly membranous staining reaction (Fig. C). No staining reaction should be seen in lymphocytes apart from a cytoplasmic staining reaction in macrophages in lamina propria. Kidney: The epithelial cells lining the Bowman’s capsule should show a weak to moderate staining reaction. Epithelial cells in the tubule should show a moderate to strong distinct staining reaction (Fig. D). Differential Diagnosis* Liver: The bile duct epithelial cells should show a distinct predominantly membranous staining reaction, while hepatocytes should be negative. 1. Adenocarcinoma vs. malignant mesothelioma. 2. Basal cell carcinoma vs. squamous cell carcinoma of the skin. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Lung adenocarcinoma. The majority of the neoplastic cells show a distinct predominantly membranous staining reaction. Figure B. Mesothelioma. The majority of the neoplastic cells are negative. Only a few cells show a positive staining reaction. Figure C. Colon. The columnar epithelial cells should show a moderate to strong staining reaction. Figure D. Kidney. The epithelial cells lining the Bowman’s capsule show a weak to moderate staining reaction, whereas epithelial cells in the collecting tubule show a moderate to strong staining reaction. 67 Antibody: Monoclonal Mouse Anti-Human Epithelial Membrane Antigen Clone: E29 Code: IR629 or IS629 Clinical Application Reaction Location Recommended Control For identification of tumors of epithelial origin in a wide variety of tissues (Fig. A and Fig. B). Membrane and cytoplasm. Breast: The epithelial cells should show a moderate to strong membranous staining reaction on the apical part of the cell membrane and, occasionally, on the entire circumference of the cell membrane (Fig. C). A granular cytoplasmic staining reaction can also be observed. Tonsil: The reactive squamous epithelial cells should show a moderate to distinct cytoplasmic staining reaction - mainly in the superficial cell layers. The plasma cells should show a weak to moderate predominantly membranous staining reaction (Fig. D). Differential Diagnosis* 1. Meningioma vs. schwannoma. 2. Chordoma vs. chondrosarcoma. 3. Metastatic carcinoma vs. adrenocortical tumor. 4. Metastatic renal cell carcinoma vs. hepatocellular carcinoma. 5. Paget’s disease vs. Bowen’s disease. * Differential diagnosis is aided by the results from a panel of antibodies. 68 Figure A. Breast ductal carcinoma. The majority of the neoplastic cells show a moderate to strong membranous and cytoplasmic staining reaction. Figure B. The mesothelioma. The malignant mesothelioma cells show a strong staining reaction in membrane and cytoplasm. Figure C. Breast. Epithelial cells show a strong staining reaction. Figure D. Tonsil. The squamous epithelial cells show a moderate to strong distinct cytoplasmic staining reaction, and the plasma cells show a weak to moderate predominantly membranous staining reaction. Antibody: Monoclonal Mouse AntiEpstein-Barr Virus, LMP-1 Clone: CS.1-4 Code: IR753 or IS753 Clinical Application Reaction Location Recommended Control For identification of Epstein-Barr virus-infected cells expressing the latent membrane protein (LMP-1) such as in Hodgkin lymphoma (Fig. A), Burkitt lymphoma/leukemia (Fig. B) and nasopharyngeal carcinoma. Membrane and cytoplasm. Hodgkin lymphoma (classical and mixed cellularity): At least focally, the Reed-Sternberg cells should show a moderate to strong predominantly membranous, but also cytoplasmic staining reaction, occasionally in a dot-like pattern (Fig. A). Epstein-Barr virus-positive Burkitt lymphoma/leukemia: At least focally, the neoplastic cells should show a moderate to strong predominantly membranous, but also cytoplasmic staining reaction, occasionally in a dot-like pattern (Fig. B). Differential Diagnosis* Epstein-Barr virus infection vs. other infection. * Differential diagnosis is aided by the results from a panel of antibodies.  Not available in the US. Figure A. Hodgkin lymphoma. Reed-Sternberg cells show a moderate to strong staining reaction for Epstein-Barr virus. Figure B. Burkitt lymphoma/leukemia. Burkitt lymphoma/leukemia cells show a strong membranous and cytoplasmic staining reaction for Epstein-Barr virus. 69 Antibody: Monoclonal Rabbit Anti-Human Ets-Related Gene (ERG) Clone: EP111 Code: IR659 NEW Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of prostate adenocarcinoma (Fig. A and Fig. B). Overexpression of the ERG gene products is associated with prostate cancer. Nuclear. Vascular system in all tissues. Endothelial cells should show a moderate to strong nuclear staining (Fig. C). Prostate adenocarcinoma vs. benign prostate tissue. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Prostate adenocarcinoma. The majority of neoplastic cells show a moderate to strong nuclear staining reaction. Figure C. Endothelial cells of the vascular system. Endothelial cells show a moderate to strong nuclear staining in virtually all tissues. 70 Figure B. Prostate adenocarcinoma. The majority of neoplastic cells show a moderate to strong nuclear staining reaction. Antibody: Monoclonal Mouse Anti-Human Estrogen Receptor a Clone: 1D5 Code: IR657 or IS657 Clinical Application Reaction Location Recommended Control For assessment of estrogen receptor status in breast carcinomas (Fig. A and Fig. B). Nucleus. Breast carcinoma with moderate estrogen receptor expression: The neoplastic cells should show a moderate staining reaction (Fig. B). Cervix: Virtually all the columnar and basal squamous epithelial cells as well as the stromal cells (with the exception of endothelial cells and smooth muscle cells) should show a moderate to strong nuclear staining reaction. The intermediate and superficial squamous epithelial cells should show a weak to moderate nuclear staining reaction (Fig. C). Differential Diagnosis* 1. Hormone receptor status in breast carcinoma. 2. Metastatic carcinoma of the breast vs. other organs. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Breast ductal carcinoma. The majority of the neoplastic cells show a distinct nuclear staining reaction. Figure C. Cervix. The columnar and basal squamous epithelial cells as well as the stromal cells show a moderate to strong and distinct nuclear staining reaction. The intermediate and superficial squamous epithelial cells show a weak to moderate nuclear staining reaction. Figure B. Breast ductal carcinoma. The majority of the neoplastic cells show a modrate staining reaction. 71 Antibody: Monoclonal Rabbit Anti-Human Estrogen Receptor a Clone: EP1 Code: IR084 or IS084 NEW Clinical Application Reaction Location Recommended Control Differential Diagnosis* For assessment of estrogen receptor status in breast cancer (Fig. A and B). Nucleus. Breast carcinoma with moderate ER expression: The neoplastic cells should show a moderate staining reaction (Fig. B). 1. Hormone receptor status in breast carcinoma. 2. Metastatic cancer of the breast vs. other organs. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Breast ductal carcinoma with positive estrogen receptor expression. Neoplastic cells show a strong nuclear staining reaction. 72 Figure B. Breast ductal carcinoma with positive estrogen receptor expression. Neoplastic cells show a moderate staining reaction. Antibody: Polyclonal Rabbit Anti-Human Gastrin Code: IR519 or IS519 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of gastrin-secreting neuroendocrine tumors (Fig. A and Fig. B). Cytoplasm. Antral mucosa of the stomach: The G cells should show a moderate to strong cytoplasmic staining reaction (Fig. C). Occasionally, a slightly diffuse staining reaction from the G cells may be seen. The epithelial cells should be negative. Gastrinomas vs. other endocrine gastrointestinal tumors. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Gastrin-producing tumor spread to the liver. The majority of the neoplastic cells show a moderate granular staining reaction. Figure B. Gastrin-producing tumor spread to the lymph node. The majority of the neoplastic cells show a strong and distinct cytoplasmic staining reaction. Figure C. Antral mucosa of the stomach. The G cells show a moderate to strong cytoplasmic staining reaction with a slight diffusion in the vicinity of the reaction. 73 Antibody: Monoclonal Mouse Anti-Human GCDFP-15 Clone: 23A3 Code: IR077 or IS077 Clinical Application Reaction Location Recommended Control For identification of metastases from breast carcinoma. (Fig. A). Cytoplasm. Breast hyperplasia: At least focally, the ductal epithelial cells should show a moderate to strong cytoplasmic reaction (Fig. B). Skin: At least focally, the epithelial cells of the sweat glands should show a moderate to strong cytoplasmic staining reaction (Fig. C). Squamous epithelial cells should be negative. Differential Diagnosis* Metastatic cancer of the breast vs. metastases from other organs. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Breast ductal carcinoma. The neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure C. Skin. Focally, the epithelial cells of the sweat glands show a moderate to strong staining reaction. 74 Figure B. Breast hyperplasia. The ductal epithelial cells show a moderate to strong staining reaction. Antibody: Polyclonal Rabbit AntiGlial Fibrillary Acidic Protein Code: IR524 or IS524 Clinical Application Reaction Location Recommended Control For identification of astrocytes in the central nervous system and related tumors (Fig. A and Fig. B). Cytoplasm. Brain: The astrocytes should show a moderate to strong cytoplasmic staining reaction (Fig. C). Appendix/Colon: Ganglion cells, e.g. in Auerbach’s and Meissner’s plexus, should show a weak to moderate staining reaction (Fig. D). Differential Diagnosis* Glioma vs. metastatic carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Astrocytoma. The majority of the neoplastic cells show a strong cytoplasmic staining reaction. Figure B. Glioblastoma. The majority of the neoplastic cells show a strong cytoplasmic staining reaction. Figure C. Brain. The astrocytes show a moderate to strong cytoplasmic staining reaction. Figure D. Colon. The ganglion cells in Meissner’s plexus show a weak to moderate staining reaction. 75 Antibody: Polyclonal Rabbit AntiHelicobacter Pylori Code: IR523 or IS523 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of helicobacter pylori infection in gastritis (Fig. A and Fig. B) and primary gastric lymphomas. Helicobacter pylori bacteria. Gastric mucosa infected with helicobacter pylori: The bacteria lining the gastric mucosa should show a moderate to strong staining reaction. No staining reaction should be seen in the epithelial cells. In the lamina propria, scattered macrophages can show a positive staining reaction (Fig. A and Fig. B). Gastritis (helicobacter pylori infection vs. other causes). * Differential diagnosis is aided by the results from a panel of antibodies.  Not currently available in the US. Figure A. Gastric mucosa infected with helicobacter pylori. Helicobacter pylori in the gastric mucosa lining show a moderate to strong staining reaction. 76 Figure B. Gastric mucosa infected with helicobacter pylori. Helicobacter pylori in the gastric mucosa lining show a moderate to strong staining reaction. Antibody: Monoclonal Mouse Anti-Human Hepatocyte Clone: OCH1E5 Code: IR624 or IS624 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For differential diagnosis of hepatocellular tumors (Fig. A and Fig. B), clear cell hepatocellular carcinomas from other clear cell malignancies, and for the distinction of hepatoblastoma, especially, the embryonal type from other small, round cell tumors of childhood. Cytoplasm. Liver: The hepatocytes should show a moderate to strong granular cytoplasmic staining reaction, while the bile duct epithelial cells should be negative (Fig. C). 1. Hepatocellular carcinoma vs. cholangiocarcinoma. 2. Hepatocellular carcinoma vs. renal cell carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Hepatocellular carcinoma. The neoplastic cells show a strong, homogeneous and granular cytoplasmic staining reaction. Figure B. Hepatocellular carcinoma. The neoplastic cells show a strong and homogeneous granular cytoplasmic staining reaction. Figure C. Liver. The hepatocytes show a moderate to strong granular cytoplasmic staining reaction. The bile duct epithelial cells are negative. 77 Antibody: Polyclonal Rabbit AntiHerpes Simplex Virus Type 1 Code: IR521 or IS521 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of herpes simplex virus infection in human tissue (Fig. A to C). Intranucleus. Lesion with herpes simplex virus infection: T cells infected with herpes simplex virus (type 1 or type 2) should show a weak to strong and occasionally diffuse intranuclear staining reaction (Fig. A to C). Herpes simplex virus infection vs. other infection. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Liver. Cells infected with herpes simplex virus show a weak to strong and occasionally diffuse intranuclear staining reaction. Figure C. Brain. Cells infected with herpes simplex virus show a moderate to strong and occasionally diffuse intranuclear staining reaction. 78 Figure B. Placenta. Cells infected with herpes simplex virus show a weak to strong and occasionally diffuse intranuclear staining reaction. Antibody: Polyclonal Rabbit Anti-Human IgD Code: IR517 or IS517 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of human IgD (delta-chains) in splenic marginal zone lymphoma (Fig. A), mantle cell lymphoma (Fig. B), B-cell chronic lymphocytic/leukemia/small lymphocytic lymphoma and rare subsets of multiple myeloma. Membrane and cytoplasm Tonsil: The majority of the mantle zone B cells should show a moderate to strong predominantly membranous reaction (Fig. C). The background should be negative or show only a minimal staining reaction. IgD vs. other subtypes of lymphomas. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Splenic marginal zone lymphoma. The neoplastic cells show a strong membranous and cytoplasmic staining reaction. Figure B. Mantle cell lymphoma. The neoplastic cells show a moderate predominantly membranous staining reaction. Figure C. Tonsil. Mantle zone B cells show a moderate to strong staining reaction. 79 Antibody: Polyclonal Rabbit Anti-Human IgG Code: IR512 or IS512 Clinical Application Reaction Location Recommended Control For identification of plasma cells and related lymphoid cells containing IgG, and for IgG plasma cell neoplasia (Fig. A). Additionally, the antibody may be used for distinguishing neoplastic monoclonal proliferation from reactive hyperplasia of plasma cells. Membrane and cytoplasm. Tonsil: 60-70% of the plasma cells should show a moderate to strong cytoplasmic staining reaction. Immunoblasts in the germinal center should also show a moderate to strong staining reaction. (Fig. B). Bone marrow: 60-70% of the plasma cells should show a strong cytoplasmic staining reaction. Differential Diagnosis* Subtyping for B-cell neoplasm: IgG subtype vs. IgM subtype vs. IgA subtype. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Plasmacytoma IgG subtype. Atypical plasma cells of plasmacytoma show a weak to strong staining reaction. 80 Figure B. Tonsil. Plasma cells and immunoblasts show a moderate to strong cytoplasmic staining reaction. Antibody: Polyclonal Rabbit Anti-Human IgM Code: IR513 or IS513 Clinical Application Reaction Location Recommended Control For identification of plasma cells and lymphoid cells containing IgM. It is also used for the classification of IgM subtype for B-cell neoplasia (Fig. A). Additionally, the antibody may be used for distinguishing neoplastic monoclonal proliferation from reactive plasma cell hyperplasia. Cytoplasm and membrane. Tonsil: Virtually all mantle zone B cells should show a weak to moderate distinct membranous staining reaction, while immunoblasts and plasma cells in the germinal center should show a moderate to strong cytoplasmic staining reaction (Fig. B). Bone marrow: About 10% of the plasma cells should be stained. Differential Diagnosis* Subtyping for B-cell neoplasm: IgM subtype vs. IgG subtype vs. IgA subtype. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. CLL IgM subtype. A strong IgM staining is seen in the neoplastic cells. Figure B. Tonsil. The mantle zone B cells show a moderate staining reaction, whereas immunoblasts and plasma cells in the germinal center show a moderate to strong cytoplasmic staining reaction. 81 Antibody: Monoclonal Mouse Anti-Human Inhibin-a Clone: R1 Code: IR058 or IS058 Clinical Application Reaction Location Recommended Control For identification of ovarian sex cord and stromal tumors such as granulosa cell tumor (Fig. A). Other positive tumors include complete hydatiform mole, gynandroblastoma and adrenal cortical adenocarcinoma. Cytoplasm. Placenta: The trophoblasts and syncytiotrophoblasts should show a moderate to strong heterogeneous and granular cytoplasmic staining reaction (Fig. B). Testis: Both Leydig cells and Sertoli cells should show a moderate to strong, distinct granular cytoplasmic staining reaction (Fig. C). Differential Diagnosis* 1. Granulosa cell tumor vs. carcinoma. 2. Adrenocortical tumor vs. renal cell carcinoma. 3. Adrenocortical tumor vs. pheochromocytoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Granulosa cell tumor. The tumor cells show a moderate to strong granular cytoplasmic staining reaction. Figure C. Testis. Leydig cells and Sertoli cells show a moderate to strong staining reaction. 82 Figure B. Placenta. The trophoblasts and the syncytiotrophoblasts show a heterogeneous cytoplasmic staining reaction. Antibody: Polyclonal Guinea Pig AntiInsulin Code: IR002 or IS002 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of insulin-producing cells in normal and neoplastic tissue (Fig. A). Cytoplasm. Pancreas: The B cells in the islets of Langerhans (Fig. B) should show a moderate to strong cytoplasmic staining reaction. The acinar epithelial cells of the pancreas should be negative. Insulinoma vs. other endocrine tumors of the pancreas. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Insulinoma. Focally, the neoplastic cells show a moderate to strong granular cytoplasmic staining reaction. Figure B. Pancreas. The B cells in the islets of Langerhans show a moderate to strong cytoplasmic staining reaction. 83 Antibody: Polyclonal Rabbit Anti-Human Kappa Light Chains Code: IR506 or IS506 Clinical Application Reaction Location Recommended Control For identification of plasma cells and lymphoid cells containing kappa light chains, and for classification of kappa light chain restriction (Fig. A and Fig. B) for monoclonal gammopathies and amyloidosis. Membrane and cytoplasm. Tonsil: Approximately 40-60 % of the B cells in the mantle zone should show a weak to moderate membranous staining reaction, while the B lymphocytes in the germinal center should be negative or only weakly demonstrated. Plasma cells and immunoblasts in the germinal center should show a moderate to strong cytoplasmic staining reaction. Some background reaction in serum, connective tissue and epithelial cells is accepted (Fig. C). Bone marrow: Approximately 40-60 % of the plasma cells should show a strong cytoplasmic staining reaction. Differential Diagnosis* IgK subtype vs. IgL subtype for B-cell neoplasm. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. B-cell lymphoma. Most neoplastic cells show a distinct membranous and cytoplasmic staining reaction. 84 Figure C. Tonsil. B cells in the mantle zone show a weak to moderate membranous staining reaction, while the B lymphocytes in the germinal center are weakly demonstrated. Plasma cells and immunoblasts in the germinal center show a moderate to strong cytoplasmic staining reaction. Figure B. Plasmacytoma. The tumor cells show a strong cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Ki-67 Antigen Clone: MIB-1 Code: IR626 or IS626 Clinical Application Reaction Location Recommended Control For identification of proliferating cells in normal and neoplastic tissues such as Burkitt lymphoma/leukemia (Fig. A), colon adenocarcinoma (Fig. B), soft-tissue sarcoma, prostatic adenocarcinoma and breast carcinoma. Nucleus and perinucleus. Tonsil: In the secondary follicles, virtually all the germinal center B cells should show a moderate to strong nuclear staining reaction - the staining is the strongest in the dark zone and the weakest in the light zone below the mantle zone (Fig. C). The parabasal squamous epithelial cells should show a weak to moderate nuclear staining reaction (Fig. D). Esophagus: The basal and parabasal epithelial cells should show a distinct nuclear staining reaction. Differential Diagnosis* 1. High grade non-Hodgkin lymphoma vs. low grade non-Hodgkin lymphoma. 2. Burkitt lymphoma/leukemia vs. other lymphoma. 3. Anal intraepithelial neoplasm vs. hyperplasia or dysplasia. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Burkitt lymphoma/leukemia. Virtually all the neoplastic cells show a distinct nuclear staining reaction. Figure B. Colon adenocarcinoma. The neoplastic cells show a distinct nuclear staining reaction, while only a few normal basal epithelial cells are stained. Figure C. Tonsil. The germinal center B cells show a moderate to strong nuclear staining reaction. Figure D. Tonsil. The parabasal squamous epithelial cells show a weak to moderate nuclear staining reaction. 85 Antibody: Polyclonal Rabbit Anti-Human Lambda Light Chains Code: IR507 or IS507 Clinical Application Reaction Location Recommended Control For identification of plasma cells and lymphoid cells containing lambda light chains, and for classification of lambda light chain restriction (Fig. A) for monoclonal gammopathies and amyloidosis. Membrane and cytoplasm. Tonsil: The mantle zone B cells should show a moderate to strong membranous staining reaction, while immunoblasts and plasma cells in the germinal center should show a moderate to strong cytoplasmic staining reaction (Fig. B). Bone marrow: Approximately 40-50% of the plasma cells should show a strong cytoplasmic staining reaction. Differential Diagnosis* IgL subtype vs. IgK subtype for B-cell neoplasm. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Plasmacytoma lambda subtype. The plasmacytoma cells show a strong cytoplasmic staining reaction. 86 Figure B. Tonsil. The B cells and plasma cells show a moderate to strong cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Mammaglobin Clone: 304-1A5 Code: IR074 or IS074 Clinical Application Reaction Location Recommended Control For identification of breast ductal carcinoma (Fig. A). Cytoplasm. Breast hyperplasia: At least focally, the ductal epithelial cells should show a moderate to strong cytoplasmic staining reaction (Fig. B). Skin: At least focally, the epithelial cells of the sweat glands should show a moderate to strong cytoplasmic staining reaction. The squamous epithelial cells should be negative (Fig. C). Differential Diagnosis* Metastatic breast carcinoma vs. other primary/metastatic tumors. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Breast ductal carcinoma. Neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure B. Breast hyperplasia. The ductal epithelial cells show a moderate to strong cytoplasmic staining reaction. Figure C. Skin. The epithelial cells of the sweat glands show a moderate to strong cytoplasmic staining reaction. 87 Antibody: Monoclonal Mouse Anti-Human Mast Cell Tryptase Clone: AA1 Code: IR640 or IS640 Clinical Application Reaction Location Recommended Control For identification of atypical or immature mast cells in mast cell leukemia and small mast cell infiltrates in cutaneous mastocytosis (Fig. A and Fig. B). Cytoplasm. Tonsil: The interfollicular mast cells should show a moderate to strong cytoplasmic staining reaction (Fig. C). Occasionally, a weak and diffuse staining pattern in the vicinity of the labeled cells may be seen. Lymphocytes should be negative. Appendix/Colon: Mast cells in the lamina propria should show a moderate to strong distinct cytoplasmic staining reaction, while the epithelial cells should be negative (Fig. D). Occasionally, a weak and diffuse staining pattern in the vicinity of the labeled cells may be seen. Differential Diagnosis* Mast cell disease vs. other inflammatory cell infiltrates. * Differential diagnosis is aided by the results from a panel of antibodies. 88 Figure A. Mastocytosis in the bone marrow. The majority of the mast cells show a strong cytoplasmic staining reaction. Figure B. Mastocytosis in the subcutis. The majority of the mast cells show a strong cytoplasmic staining reaction. Figure C. Tonsil. The interfollicular mast cells show a strong cytoplasmic staining reaction. A weak and diffuse staining pattern in the vicinity of the labeled cells is seen. Figure D. Colon. Mast cells in the lamina propria show a moderate to strong cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human Melan-A Clone: A103 Code: IR633 or IS633 Clinical Application Reaction Location Recommended Control For identification of melanoma (Fig. A). Melan-A is also expressed by various tumors such as granulosa cell tumor (Fig. B), adrenocortical carcinoma and angiomyolipoma. Cytoplasm. Skin: The melanocytes in the basal layer of the epidermis and nevus cells should show a strong distinct cytoplasmic staining reaction and squamous epithelial cells should be negative (Fig. C). Adrenal gland: Virtually all the adrenal cortical cells should show a weak to moderate distinct granular staining reaction throughout all zones of the gland (Fig. D). Differential Diagnosis* 1. Spindle cell melanoma vs. spindle cell carcinoma. 2. Melanoma vs. lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Melanoma. The metastatic melanoma cells show a strong cytoplasmic staining reaction for melan-A. Figure B. Granulosa cell tumor. The majority of the neoplastic cells show a strong granular cytoplasmic staining reaction. Figure C. Skin. The melanocytes in the basal layer of the epidermis show a moderate to strong cytoplasmic staining reaction. Figure D. The adrenal cortical cells show a weak to moderate staining reaction. 89 Antibody: Monoclonal Mouse Anti-Human Melanosome Clone: HMB45 Code: IR052 or IS052 Clinical Application Reaction Location Recommended Control For identification of melanocytes with immature melanosome formation in normal skin, nevus and melanoma tissue. Cytoplasm. Melanoma: The majority of the melanoma cells should show a moderate to strong, distinct and granular cytoplasmic staining reaction (Fig. A and Fig. B). Nevus: The nevus cells in the dermis should show a moderate to strong distinct cytoplasmic staining reaction. (Fig. C). Differential Diagnosis* 1. Melanoma vs. carcinoma. 2. Angiomyolipoma vs. sarcomatoid renal cell carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Melanoma. The skin melanoma cells show a moderate to strong cytoplasmic staining reaction. Figure C. Skin nevus. The nevus cells in the dermis and the melanocytes in the basal layer of the epidermis show a moderate to strong granular cytoplasmic staining reaction. 90 Figure B. Metastatic melanoma. The metastatic melanoma cells show a strong cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human MUC2 Clone: CCP58 Code: IR658 NEW Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of mucinous adenocarcinoma of gastrointestinal origin (Fig. A) and intestinal metaplasia in Barrett’s esophagus (Fig. B). Cytoplasm. Colon: Goblet cells should show a moderate to strong cytoplasmic staining reaction (Fig. C). Colon adenocarcinoma metastatic to the ovary vs. primary mucinous ovary tumor. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma metastatic to the ovary. The neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure B. Barrett’s esophagus. The neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure C. Colon. Goblet cells in the tubular glands show a moderate to strong cytoplasmic staining reaction 91 Antibody: Monoclonal Mouse Anti-Human MUM1 Protein Clone: MUM1p Code: IR644 or IS644 Clinical Application Reaction Location Recommended Control For subclassification of lymphoid malignancies (Fig. A and Fig. B). Nucleus and cytoplasm. Appendix/Colon: Plasma cells in the lamina propria should show a moderate to strong nuclear staining reaction (Fig. C). The epithelial cells should be negative. Tonsil: In the germinal center, activated B cells should show a weak to moderate nuclear staining reaction (Fig. D). The interfollicular plasma cells should show a moderate to strong nuclear staining reaction. Only a minimal cytoplasmic staining reaction should be seen. The squamous epithelial cells should be negative. Differential Diagnosis* Subtyping of diffuse large B-cell lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. 92 Figure A. Myeloma. The majority of the neoplastic cells show a strong nuclear staining reaction. Figure B. Classic Hodgkin lymphoma. Reed-Sternberg cells show a nuclear staining reaction. Figure C. Appendix. Plasma cells in lamina propria show a moderate to strong nuclear staining reaction. Only a minimal cytoplasmic staining reaction is seen. Figure D. Tonsil. Activated B cells in the germinal center show a weak to moderate nuclear staining reaction, and interfollicular plasma cells show a moderate to strong nuclear staining reaction. Only a minimal cytoplasmic staining reaction is seen. Antibody: Monoclonal Mouse Anti-Human MutL Protein Homolog 1 (MLH1) Clone: ES05 Code: IR079 or IS079 Clinical Application Reaction Location Recommended Control For differential identification of colorectal carcinoma. When deficient, the MutL Protein Homolog 1 (MLH1) is associated with the onset of hereditary non-polyposis colorectal cancer (HNPCC) (Fig. A and Fig. B). Nucleus. Appendix/Colon: Virtually all cells should show a distinct nuclear staining reaction. The basal epithelial cells should show a moderate to strong staining reaction, whereas the luminal epithelial cells and smooth muscle cells at least should show a weak to moderate staining reaction (Fig. C). Tonsil: Virtually all cells should show a distinct nuclear reaction. Germinal center cells should show a moderate to strong staining reaction, whereas the mantle zone B and T cells should at least show a weak to moderate staining reaction (Fig. D). Differential Diagnosis* 1. HNPCC vs. other sporadic colorectal cancer. 2. Microsatellite instability evaluation in various cancer types such as e.g. endometrial and prostate adenocarcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma with loss of MLH1 protein. The neoplastic cells show no nuclear staining reaction, while entrapped stromal cells show a moderate to strong nuclear staining reaction. Figure B. Colon adenocarcinoma with intact MLH1 gene function. Both the neoplastic cells, stromal cells and remnants of benign epithelial cells show a moderate to strong nuclear staining reaction. Figure C. Appendix. Virtually all of the epithelial cells and stromal cells show a moderate to strong nuclear staining reaction. Figure D. Tonsil. The majority of the cells show a moderate to strong nuclear staining reaction. 93 Antibody: Monoclonal Mouse Anti-Human MutS Protein Homolog 2 (MSH2) Clone: FE11 Code: IR085 NEW Clinical Application Reaction Location Recommended Control Differential Diagnosis* For the evaluation of colorectal carcinoma. MSH2 protein deficiency, as indicated by a loss of staining in tumor cells, identifies colorectal cancers with defects in DNA mismatch repair. This usually results from germline mutations in the MSH2 gene that confer a hereditary predisposition to colorectal and to a lesser degree other cancers, known collectively as Lynch syndrome (Fig. A and B). Nucleus. Appendix/Colon: Virtually all cells should show a distinct nuclear staining reaction. The basal epithelial cells should show a moderate to strong staining reaction whereas the luminal epithelial cells and smooth muscle cells at least should show a weak to moderate staining reaction (Fig. C). Delayed fixation or long term storage of cut sections may reduce staining intensity which may impact interpretation. Cancers associated with MSH2 mutation or loss of expression vs. MSH2 intact cancers. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma with loss of MSH2 protein. The neoplastic cells show no nuclear staining reaction, adjacent normal stromal cells show a moderate to strong nuclear staining reaction. Figure C. Appendix. Virtually all of the epithelial cells and stromal cells show a moderate to strong nuclear staining reaction. 94 Figure B. Colon adenocarcinoma with intact MSH2 expression. The neoplastic cells, stromal cells and remnants of benign epithelial cells show a moderate to strong nuclear staining reaction. Antibody: Monoclonal Rabbit Anti-Human MutS Protein Homolog 6 (MSH6) Clone: EP49 Code: IR086 NEW Clinical Application Reaction Location Recommended Control Differential Diagnosis* For the evaluation of colorectal carcinoma. Loss of MSH6 protein in colorectal cancers identifies tumors with defects in DNA mismatch repair. This is most often a consequence of loss of expression of its heterodimeric partner MSH2, but also rarely results from germline mutations in the MSH6 gene that confer a hereditary predisposition to colorectal and to a lesser degree other cancers, known collectively as Lynch syndrome (Fig. A and B). Nucleus. Appendix/Colon: Virtually all cells should show a distinct nuclear staining reaction. The basal epithelial cells should show a moderate to strong staining reaction whereas the luminal epithelial cells and stromal cells at least should show a weak to moderate staining reaction (Fig. C). Delayed fixation or long term storage of cut sections may reduce staining intensity which may impact interpretation. Cancers associated with MSH6 mutation or loss of expression vs. MSH6 intact cancers. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma with loss of MSH6 protein. The neoplastic cells show no nuclear staining reaction, while entrapped stromal cells show a moderate to strong nuclear staining reaction. Figure B. Colon adenocarcinoma with intact MSH6 expression. The neoplastic cells, stromal cells and remnants of benign epithelial cells show a moderate to strong nuclear staining reaction. Figure C. Appendix. Virtually all of the epithelial cells, stromal cells, and smooth muscle cells show a moderate to strong nuclear staining reaction. 95 Antibody: Polyclonal Rabbit Anti-Human Myeloperoxidase Code: IR511 or IS511 Clinical Application Reaction Location Recommended Control For differential diagnosis between lymphoid and myeloid tumors as myeloid tumors are generally positive and lymphoid tumors negative. For example, myeloblasts and immature myeloid cells of acute myelogenous leukemia (Fig. A), monomyelocytic leukemia and erythroleukemia are positive for myeloperoxidase. Cytoplasm. Liver: The neutrophils and Kupffer cells should show a strong granular cytoplasmic staining reaction and hepatocytes should be negative or show a weak staining reaction (Fig. B). Tonsil: The neutrophils and eosinophils in the interfollicular zones and the germinal center macrophages should show a moderate to strong granular cytoplasmic staining reaction (Fig. C). Differential Diagnosis* Leukemia vs. lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Acute myeloid leukemia (M4). A strong granular cytoplasmic staining reaction is seen in part of the neoplastic cells, and a weak or absent staining is observed in the monocytes. Figure C. Tonsil. The neutrophils and eosinophils show a moderate to strong granular cytoplasmic staining reaction. 96 Figure B. Liver. The neutrophils and Kupffer cells show a moderate to strong staining reaction. Antibody: Monoclonal Mouse AntiMyogenin Clone: F5D Code: IR067 or IS067 Clinical Application Reaction Location Recommended Control For identification of rhabdomyosarcoma (Fig. A) and Wilms’ tumor (Fig. B). Nucleus. Rhabdomyosarcoma: At least focally, the neoplastic cells should show a moderate to strong nuclear reaction and no, or only a minimal, cytoplasmic reaction. No background staining should be seen (Fig. A). Leiomyosarcoma: No staining should be seen in the neoplastic cells (Fig. C). Differential Diagnosis* 1. Rhabdomyosarcoma vs. leiomyosarcoma. 2. Rhabdomysosarcoma vs. other small round cell tumors. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Rhabdomyosarcoma. Tumor cells show a moderate to strong nuclear staining reaction. Figure B. Wilms’ tumor. Some tumor cells show a strong nuclear staining reaction. Figure C. Leiomyosarcoma. Tumor cells are negative for myogenin. 97 Antibody: Monoclonal Mouse Anti-Human Neurofilament Protein Clone: 2F11 Code: IR607 or IS607 Clinical Application Reaction Location Recommended Control For identification of neurons (axons) of the central and peripheral nervous system, and for identification of tumors with neuronal differentiation as well as Merkel cell carcinoma (Fig. A). Cytoplasm. Appendix/Colon: The ganglion cells and the large axons in the plexus of Auerbach should show a moderate to strong cytoplasmic staining reaction, whereas the axons in the muscularis externa should show a weak to moderate staining reaction. Smooth muscle cells and epithelium should be negative (Fig. B). Brain: All neurons and axonal processes should show a moderate to strong fibrillar cytoplasmic staining reaction (Fig. C). Differential Diagnosis* 1. Neuroblastoma vs. Wilms’ tumor. 2. Merkel cell carcinoma vs. lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Merkel cell carcinoma. A strong heterogeneous, cytoplasmic and dot-like staining reaction is seen in the neoplastic cells. Figure C. Cerebellum. All neurons and axonal processes show a moderate to strong fibrillar cytoplasmic staining reaction. 98 Figure B. Colon. The ganglion cells and the large axons in the Auerbach´s plexus show a moderate to strong cytoplasmic staining reaction, whereas the axons in the muscularis externa show a weak to moderate staining reaction. Antibody: Monoclonal Mouse Anti-Human Neuron-Specific Enolase Clone: BBS/NC/VI-H14 Code: IR612 or IS612 Clinical Application Reaction Location Recommended Control For identification of both normal neuronal and neuroendocrine cells and corresponding tumors such as schwannoma (Fig. A) and carcinoid tumors (Fig. B). Nucleus and cytoplasm. Appendix/Colon: A moderate to strong granular cytoplasmic and nuclear staining reaction should be seen in the neuroendocrine cells of the mucosa and in the ganglion cells. The axons should show a weak to moderate granular cytoplasmic staining reaction. The epithelial cells should be negative (Fig. C). Pancreas: The Langerhans’ islets and single neuroendocrine cells in the pancreatic ducts should show a strong granular cytoplasmic and nuclear staining reaction. Differential Diagnosis* 1. Schwannoma vs. meningioma. 2. Carcinoid tumor vs. carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Schwannoma. The neoplastic cells show a weak to moderate staining reaction. Figure C. Colon. The neuroendocrine cells of the mucosa and the ganglion cells show a moderate to strong granular cytoplasmic and nuclear staining reaction. The axons show a weak to moderate granular cytoplasmic staining reaction. Figure B. Carcinoid tumor. The neoplastic cells show a moderate to strong granular cytoplasmic staining reaction. 99 Antibody: Monoclonal Mouse Anti-Human Nucleophosmin Clone: 376 Code: IR652 or IS652 Clinical Application Reaction Location Recommended Control For identification of both wild-type nucleophosmin (NPM) (Fig. A) and the mutated counterpart NPMc+ (Fig. B). It is useful for the identification of leukemic blasts in a subgroup of acute myeloid leukemia cases with a normal karyotype. Nucleus and cytoplasm. Liver: The majority of the normal hepatocytes should show a distinct or reticulated moderate to strong nuclear staining reaction, while some nuclei are negative. Mitotic and post-mitotic cells should show a weak to moderate cytoplasmic staining reaction (Fig. C). Cerebellum: The majority of the normal neurons should show a moderate to strong distinct nuclear staining reaction, whereas some nuclei are negative. Large Purkinje neurons and some small granular neurons should show a weak to moderate cytoplasmic staining reaction (Fig. D). Differential Diagnosis* Acute myeloid leukemia with normal karyotype vs. acute myeloid leukemia with abnormal karyotype. * Differential diagnosis is aided by the results from a panel of antibodies. 100 Figure A. Acute myeloid leukemia (NPM1 Exon 12 normal; NPMc-). The majority of the leukemic blasts show a distinct nuclear staining reaction and no cytoplasmic staining reaction. Figure B. Acute myeloid leukemia (NPM1 Exon 12 mutant; NPMc+). The majority of the leukemic blasts show a distinct nuclear staining reaction and a moderate to strong cytoplasmic staining reaction. Figure C. Liver. The majority of the normal hepatocytes show a moderate to strong nuclear staining reaction, while some nuclei are negative. Mitotic and post-mitotic cells show a weak to moderate cytoplasmic staining reaction. Figure D. Brain. The majority of the normal neurons show a distinct nuclear staining reaction. Large Purkinje neurons and some small granular neurons show a weak to moderate cytoplasmic staining reaction. Antibody: Monoclonal Mouse Anti-Human p53 Protein Clone: DO-7 Code: IR616 or IS616 Clinical Application Reaction Location Recommended Control For identification of wild-type and mutant-type p53 protein and accumulation in human neoplasia such as serous ovarian carcinoma (Fig. A), transitional cell carcinoma of the bladder (Fig. B), carcinoma of breast, lung and endometrium, follicular lymphoma and mantle cell lymphoma. Nucleus. Colon adenocarcinoma with normal colon tissue: The majority of the neoplastic cells should show a moderate to strong distinct nuclear staining reaction. The normal epithelial cells should be negative, except for the basal cells that may show a weak to moderate nuclear staining reaction (Fig. C). Esophagus: The parabasal layer of the epithelial cells should show a distinct nuclear staining reaction. Differential Diagnosis* 1. Malignant mesothelioma or carcinoma of pleural effusion vs. reactive mesothelium. 2. Uterine serous carcinoma vs. endometrioid carcinoma. 3. Lung sarcoma vs. lung inflammatory pseudotumor. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Serous ovarian carcinoma. Virtually all the neoplastic cells show a moderate to strong nuclear staining reaction. Figure C. Colon adenocarcinoma. The neoplastic cells show a moderate to strong nuclear staining reaction, while normal colon epithelial cells are negative, except for a few scattered basal cells that show a weak to moderate nuclear staining reaction. Figure B. Transitional cell carcinoma of the bladder. The neoplastic cells show a focal moderate to strong nuclear staining reaction. 101 Antibody: Monoclonal Mouse Anti-Human Placental Alkaline Phosphatase Clone: 8A9 Code: IR779 or IS779 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of malignant germ cell tumors (Fig. A and Fig. B) such as dysgerminoma and embryonal carcinoma. Membrane and cytoplasm. Placenta: The brush border of the syncytio- and cytotrophoblasts should show a moderate to strong and predominantly membranous staining reaction. The cytoplasmic compartment of the syncytiotrophoblasts and trophoblasts should show a weak to moderate cytoplasmic staining reaction. Some cytoplasmic staining in the smooth muscle cells and myofibroblasts is also acceptable (Fig. C). 1. Seminoma vs. carcinoma. 2. Seminoma vs. melanoma vs. lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Seminoma. The majority of the neoplastic cells show a moderate to strong predominantly membranous, but also cytoplasmic staining reaction. 102 Figure C. Placenta. The brush border of the syncytio- and cytotrophoblasts show a moderate to strong membranous staining reaction, whereas the cytoplasmic compartment of the syncytio- and cytotrophoblasts show a weak to moderate staining reaction. Figure B. Testis with intratubular germ cell neoplasia. The neoplastic cells show a moderate to strong predominantly membranous, but also cytoplasmic staining reaction. Normal germ cells are negative. Antibody: Monoclonal Mouse AntiPneumocystis Jiroveci Clone: 3F6 Code: IR635 or IS635 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of Pneumocystis jiroveci, previously known as P. carinii (P. jiroveci) (Fig. A and Fig. B). Membrane. Lesion with Pneumocystis jiroveci infection (lung): The cyst walls of the Pneumocystis jiroveci should show a moderate to strong staining reaction, while the trophozites should show a weak to moderate, diffuse and granular reaction. No reaction should be seen in epithelial or lymphatic cells (Fig. A and Fig. B). Pneumocystis jiroveci infection vs. other infection. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Lung infected with Pneumocystis jiroveci. The cyst walls of the Pneumocystis Jiroveci show a moderate to strong staining reaction, while the trophozites show a weak to moderate, diffuse and granular staining reaction. Figure B. Lung infected with Pneumocystis jiroveci. The cyst walls of the Pneumocystis Jiroveci show a moderate to strong staining reaction, while the trophozites show a weak to moderate, diffuse and granular staining reaction. 103 Antibody: Monoclonal Rabbit Anti-Human Postmeiotic Segregation Increased 2 (PMS2) Clone: EP51 Code: IR087 NEW Clinical Application Reaction Location Recommended Control Differential Diagnosis* For the evaluation of colorectal carcinoma. Loss of PMS2 protein in colorectal cancers identifies tumors with defects in DNA mismatch repair. This is most often a consequence of loss of expression of its heterodimeric partner MLH1 via either MLH1 hypermethylation or less often a germline mutation in MLH1 both associated with hereditary predisposition to colorectal and to a lesser degree other cancers, known collectively as Lynch syndrome (Fig. A and B). Nucleus. Appendix/Colon: Virtually all cells should show a distinct nuclear staining reaction. The basal epithelial cells should show a moderate to strong staining reaction whereas the luminal epithelial cells and stromal cells at least should show a weak to moderate staining reaction (Fig. C). Delayed fixation or long term storage of cut sections may reduce staining intensity which may impact interpretation. Cancers associated with PMS2 mutation or loss of expression vs. PMS2 intact cancers. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Colon adenocarcinoma with loss of PMS2 protein. The neoplastic cells show no nuclear staining reaction, while stromal cells, lymphocytes and residual normal epithelial cells show a moderate to strong nuclear staining reaction. Figure C. Appendix. Virtually all of the epithelial cells and stromal cells show a moderate to strong nuclear staining reaction. 104 Figure B. Colon adenocarcinoma with intact PMS2 expression. Virtually all of the neoplastic cells, stromal cells and remnants of benign epithelial cells show a moderate to strong nuclear staining reaction. Antibody: Monoclonal Mouse Anti-Human Progesterone Receptor Clone: PgR 636 Code: IR068 or IS068 Clinical Application Reaction Location Recommended Control For measuring of the relative level of expression for progesterone receptor in breast cancer tissue (Fig A). It also labels meningioma cells (Fig. B). Nucleus. Cervix: A strong and distinct nuclear staining reaction should be seen in the columnar epithelial cells, the basal squamous epithelial cells and the stromal cells in the uterine cervix (Fig. C). Breast (female 15-45 yrs): Normal epithelial cells in ducts and lobules should show a moderate to strong nuclear staining reaction. Some cytoplasmic staining is acceptable. Differential Diagnosis* 1. Meningioma vs. schwannoma. 2. Endometrial stromal sarcoma vs. monophasic synovial sarcoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Breast ductal carcinoma. The neoplastic cells show a strong nuclear staining reaction. Figure B. Meningioma. Most neoplastic cells show a distinct nuclear staining reaction. Figure C. Uterine cervix. Epithelial cells and stromal cells show a strong staining reaction. Figure D. Breast. Ductal epithelial cells show a moderate to strong nuclear staining reaction. 105 Antibody: Polyclonal Rabbit Anti-Human Prostate-Specific Antigen Code: IR514 or IS514 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of tumors of prostatic origin (Fig. A and Fig. B). Except for prostate glands and prostatic epithelial neoplasia, bladder urothelium, urethra, periurethral glands and seminal vesicles are also stained positive for prostate-specific antigen. Cytoplasm. Normal prostate and benign prostatic hyperplasia: The majority of the prostate luminal epithelial cells should show a moderate to strong cytoplasmic staining reaction. A weak staining of the stromal compartment is accepted (Fig. C). Metastatic prostatic carcinoma vs. metastatic tumors of non-prostatic origin. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Prostatic adenocarcinoma. The neoplastic cells and the hyperplastic glands show a moderate to strong and diffuse cytoplasmic staining reaction. Figure C. Prostate. The prostate luminal epithelial cells show a strong cytoplasmic staining reaction. 106 Figure B. Prostatic adenocarcinoma. The neoplastic cells show a heterogeneous staining reaction. Antibody: Monoclonal Mouse Anti-Human Renal Cell Carcinoma Marker Clone: SPM314 Code: IR075 or IS075 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of renal cell carcinoma vs. non-renal cell tumors (Fig. A). Membrane and cytoplasm. Kidney: The epithelial cells of the proximal tubules should show a moderate to strong predominantly membranous staining reaction (Fig. B). 1. Renal cell carcinoma vs. hepatocellular carcinoma. 2. Renal cell carcinoma vs. urothelial carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Renal cell carcinoma (clear cell type). The majority of the neoplastic cells show a moderate to strong predominantly membranous staining reaction. Figure B. Kidney. The epithelial cells of the proximal tubules show a moderate to strong membranous and cytoplasmic staining reaction. 107 Antibody: Polyclonal Rabbit AntiS100 Code: IR504 or IS504 Clinical Application Reaction Location Recommended Control Primarily for initial screening of melanoma (Fig. A). S100 protein is found in many tumors with neuroectodermal origin such as schwannoma (Fig. B) and neurofibromas. It is also found in Langerhans’ cell histiocytosis and chondroblastoma. Nucleus and cytoplasm. Appendix/Colon: The satellite cells and the Schwann cells of the peripheral nerves should show a moderate to strong cytoplasmic and nuclear staining reaction. Adipocytes should show a weak to moderate staining reaction. Macrophages should also be positive. No staining should be seen in the epithelial and smooth muscle cells (Fig. C and D). Skin: Nerves and melanocytes in the basal layer of the epidermis should show a strong cytoplasmic and nuclear staining reaction. Differential Diagnosis* 1. Melanoma vs. lymphoma. 2. Melanoma vs. leiomyosarcoma. 3. Spindle cell melanoma vs. spindle cell carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. 108 Figure A. Malignant melanoma. The neoplastic cells show a diffuse nuclear and cytoplasmic staining reaction. Figure B. Schwannoma. Most neoplastic cells show a strong nuclear and cytoplasmic staining reaction. Figure C. Colon. The satellite cells and the Schwann cells of the peripheral nerves show a strong cytoplasmic and nuclear staining reaction. Figure D. Colon. The adipocytes show a weak to moderate staining reaction. Antibody: Monoclonal Mouse Anti-Human Smooth Muscle Actin Clone: 1A4 Code: IR611 or IS611 Clinical Application Reaction Location Recommended Control For identification of smooth muscle cells, myofibroblasts, and myoepithelial cells and their tumors such as leiomyoma (Fig. A) and leiomyosarcoma (Fig. B). Cytoplasm. Appendix/Colon: All the smooth muscle cells in vessel walls, muscle layers and lamina muscularis mucosa should show a moderate to strong cytoplasmic staining reaction. The smooth muscle cells lining the epithelial surface should be demonstrated. No staining reaction should be seen in the epithelial cells (Fig. C). Liver: The smooth muscle cells lining the sinusoids should show a weak to moderate cytoplasmic staining reaction (Fig. D). Breast: A strong cytoplasmic staining of the myoepithelial cells around the ducts and lobules as well as a strong staining reaction of the smooth muscle cells in the vessel walls should be seen. Differential Diagnosis* 1. Leiomyosarcoma vs. giant gastrointestinal stromal tumor. 2. Breast ductal carcinoma in situ vs. breast microinvasive carcinoma or adenocarcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Uterine leiomyoma. The majority of the neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure B. Leiomyosarcoma. The majority of the neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure C. Colon. The smooth muscle cells show a moderate to strong cytoplasmic staining reaction. Figure D. Liver. The smooth muscle cells lining the sinusoids show a weak to moderate cytoplasmic staining reaction. 109 Antibody: Monoclonal Mouse Anti-Human Smooth Muscle Myosin Heavy Chain Clone: SMMS-1 Code: IR066 or IS066 Clinical Application Reaction Location Recommended Control For identification of myoepithelial cells in the breast, and for identification of smooth muscle neoplasm. Myoepithelial cells are generally present in breast hyperplasia and ductal carcinoma in situ, and absent in invasive breast carcinoma (Fig. A and Fig. B). Cytoplasm. Uterus: The smooth muscle cells of the myometrium should be demonstrated (Fig. C). Appendix: The smooth muscle cells in the muscle layers should show a moderate to strong cytoplasmic staining reaction, and the smooth muscle cells of small vessels should show a weak to moderate staining reaction (Fig. D). The epithelial cells should be negative. Differential Diagnosis* Ductal carcinoma in situ vs. microinvasion vs. invasive carcinoma of the breast. * Differential diagnosis is aided by the results from a panel of antibodies. 110 Figure A. Breast hyperplasia. The myoepithelial cells around the ducts and the smooth muscle cells in the vessel walls show a strong staining reaction. Figure B. Breast invasive ductal carcinoma with ductal carcinoma in situ. The myoepithelial cells in the ductal carcinoma in situ show decreased expression of smooth muscle heavy chain myosin, while the staining is absent or disrupted in the invasive areas. Figure C. Uterus. Smooth muscle cells of the myometrium show a moderate to strong staining reaction. Figure D. Appendix. Smooth muscle cells in muscle layers and blood vessels show a moderate to strong cytoplasmic staining reaction. Antibody: Monoclonal Mouse AntiSynaptophysin Clone: SY38 Code: IR776 or IS776 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of a wide spectrum of neuroendocrine neoplasms and tumors with neuroendocrine differentiation. These include the neural tumors (neuroblastoma, ganglioneuroblastoma, ganglioneuroma, pheochromocytoma and paraganglioma), the epithelial tumors (pancreatic islet cell neoplasm, medullary thyroid carcinoma, pituitary and parathyroid adenoma, and carcinoids of bronchopulmonary and gastrointestinal tract), and tumors with neuroendocrine differentiation (small (Fig. A) and non-small cell cancer of lung, Merkel cell carcinoma (Fig. B) and extrapulmonary small cell cancer). Cytoplasm. Appendix/Colon: The neuroendocrine cells in the epithelial surface should show a moderate to strong cytoplasmic staining reaction, while the epithelial cells should be negative. The axons of the peripheral nerves in the mucosa, submucosa and the muscularis propria should show a weak to moderate granular cytoplasmic staining reaction (Fig. C). 1. Carcinoid tumor vs. carcinoma. 2. Merkel cell carcinoma vs. basal cell carcinoma. 3. Small cell carcinoma of lung vs. lymphoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Small cell lung carcinoma. The majority of the neoplastic cells show a strong distinct cytoplasmic and focally dot-like staining reaction. Figure C. Colon. The neuroendocrine cells in the epithelial surface show a moderate to strong cytoplasmic staining reaction. The axons of the peripheral nerves in the mucosa, submucosa and the muscularis propria show a weak to moderate granular cytoplasmic staining reaction. Figure B. Merkel cell carcinoma. The majority of the neoplastic cells show a strong distinct cytoplasmic and focally dot-like staining reaction. 111 Antibody: Polyclonal Rabbit AntiTerminal Deoxynucleotidyl Transferase (TdT) Code: IR001 or IS001 Clinical Application Reaction Location Recommended Control For identification of precursor B- and T-cell lymphoblastic lymphoma/leukemia, and for identification of thymoma (Fig. A and Fig. B). Nucleus. Thymus: The subcapsular and cortical thymocytes should show a moderate to strong distinct nuclear staining reaction, whereas the medullar thymocytes should be negative (Fig. C). Tonsil: In the interfollicular zone, a few perisinusoidal cells can show a distinct nuclear staining reaction. All other cells in the tonsil should be negative. Differential Diagnosis* Lymphoblastic lymphoma/leukemia vs. myeloid leukemia/sarcoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Thymoma. The thymocytes (T lymphoblasts) show a strong nuclear staining reaction. Figure C. Adult thymus. The subcapsular and cortical thymocytes show a strong distinct nuclear staining reaction. 112 Figure B. Thymoma. The thymocytes (T lymphoblasts) show a strong nuclear staining reaction. Antibody: Polyclonal Rabbit Anti-Human Thyroglobulin Code: IR509 or IS509 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of tumors of thyroid origin such as thyroid follicular carcinoma (Fig. A), papillary thyroid carcinoma (Fig. B), Hürthle cell tumor of thyroid, and anaplastic carcinoma of thyroid. Cytoplasm. Thyroid: The cuboidal to columnar follicular epithelial cells should show a weak to moderate cytoplasmic staining reaction, while the extracellular colloids should show a moderate to strong staining reaction (Fig. C). 1. Thyroid follicular carcinoma vs. thyroid medullary carcinoma. 2. Thyroid carcinoma vs. metastatic renal cell carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Thyroid follicular carcinoma. The neoplastic cells show a strong cytoplasmic staining reaction. Figure B. Papillary thyroid carcinoma. The neoplastic cells show a strong cytoplasmic staining reaction. Figure C. Thyroid. The cuboidal to columnar follicular epithelial cells show a weak to moderate cytoplasmic staining reaction. The extracellular colloids show a moderate to strong staining reaction. 113 Antibody: Monoclonal Mouse AntiThyroid Transcription Factor (TTF-1) Clone: 8G7G3/1 Code: IR056 or IS056 Clinical Application Reaction Location Recommended Control For differential diagnosis of primary vs. metastatic tumors in the lung and thyroid. The antibody labels normal cells of thyroid and lung as well as corresponding tumors like thyroid papillary carcinoma (Fig. A) and lung adenocarcinoma (Fig. B). Mesothelioma is negative with this marker. Nucleus. Thyroid: Virtually all thyroid follicular epithelial cells should show a moderate to strong distinct nuclear staining reaction with no, or only a minimal, cytoplasmic or background staining reaction (Fig. C). Lung: The type II pneumocyte cells and the Clara cells lining the alveolar walls should show a moderate to strong distinct nuclear staining reaction. If present, the columnar epithelial cells of the respiratory ducts should be negative or show a weak nuclear staining reaction (Fig. D). Differential Diagnosis* 1. Thyroid carcinoma vs. metastatic renal cell carcinoma. 2. Lung small cell carcinoma vs. Merkel cell carcinoma. With this particular antibody TTF-1 immunoreactivity was demonstrated in the majority of pulmonary atypical carcinoids but was rare in typical carcinoids. * Differential diagnosis is aided by the results from a panel of antibodies. 114 Figure A. Lung small cell carcinoma. The neoplastic cells show a moderate to strong nuclear staining reaction. Figure B. Thyroid follicular carcinoma. The tumor cells show a moderate to strong nuclear staining reaction. Figure C. Thyroid. The thyroid follicular epithelial cells show a moderate to strong distinct nuclear staining reaction with no, or only a minimal, cytoplasmic or background staining reaction. Figure D. Lung. The type II pneumocytes lining the alveolar walls show a moderate to strong nuclear staining reaction. The epithelial cells of the respiratory ducts are negative or show a weak nuclear staining reaction. Antibody: Monoclonal Mouse Anti-Human Tyrosinase Clone: T311 Code: IR061 or IS061 Clinical Application Reaction Location Recommended Control For identification of melanocytic lesions and melanoma (Fig. A and Fig. B). Cytoplasm. Skin: The melanocytes in the basal layer of the epidermis should show a weak to moderate distinct cytoplasmic staining reaction, and no staining should be seen in the squamous epithelial cells and eccrine glands (Fig. C). Nevus: A moderate to strong distinct granular cytoplasmic staining reaction should be seen in the nevus cells of the dermis and the melanocytes in the basal layer of the epidermis (Fig. D). Differential Diagnosis* Melanoma vs. carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Melanoma. The neoplastic cells show a strong granular cytoplasmic staining reaction. Figure B. Melanoma. The neoplastic cells show a moderate to strong cytoplasmic staining reaction. Figure C. Skin. The melanocytes in the basal layer of the epidermis show a weak to moderate distinct cytoplasmic staining reaction. Figure D. Nevus. The nevus cells of the dermis and the melanocytes in the basal layer of the epidermis show a moderate to strong granular cytoplasmic staining. 115 Antibody: Monoclonal Mouse AntiVillin Clone: 1D2 C3 Code: IR076 or IS076 Clinical Application Reaction Location Recommended Control For identification of colon adenocarcinomas (Fig. A) and renal cell carcinoma (Fig. B). Membrane and cytoplasm. Appendix: The appendiceal enterocytes should show a moderate to strong predominantly membranous staining reaction (Fig. C). The cytoplasm will typically show a diffuse and weak staining reaction. Liver: The majority of the hepatocytes should show a weak to moderate membranous staining reaction with no, or only a minimal, cytoplasmic staining reaction (Fig. D). Differential Diagnosis* Adenocarcinoma especially gastrointestinal tract vs. mesothelioma or non-epithelial tumors. * Differential diagnosis is aided by the results from a panel of antibodies. 116 Figure A. Colon adenocarcinoma. The neoplastic cells show a strong membranous and cytoplasmic staining reaction. Figure B. Renal cell carcinoma. The majority of the neoplastic cells show a strong predominantly membranous staining reaction. Figure C. Appendix. The appendiceal enterocytes show a strong membranous and cytoplasmic staining reaction. Figure D. Liver. Hepatocytes show a weak to moderate membranous staining reaction. Antibody: Monoclonal Mouse AntiVimentin Clone: V9 Code: IR630 or IS630 Clinical Application Reaction Location Recommended Control For identification of cells of mesenchymal origin in normal and neoplastic tissues such as B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (Fig. A). Cytoplasm. Tonsil: All peripheral cells should show a distinct cytoplasmic staining reaction. The cells in the capsule/mantle zone of the secondary follicles should show a moderate to strong staining reaction. Stromal cells and endothelial cells should be demonstrated (Fig. B). Liver: Sinusoid smooth muscle cells in the liver should show a weak to moderate cytoplasmic staining reaction (Fig. C). Appendix/Colon: The interepithelial cells should show a moderate to strong distinct cytoplasmic staining with no reaction in the epithelial cells. Smooth muscle cells in the lamina propria should show a moderate to strong focal cytoplasmic staining reaction. Differential Diagnosis* Endometrioid carcinoma vs. endocervical carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. The majority of the neoplastic cells show a distinct cytoplasmic staining reaction. Figure B. Tonsil. Lymphocytes and endotehelial cells show a strong cytoplasmic staining reaction. Figure C. Liver. The macrophages and lymphocytes show a weak to moderate staining reaction, while the hepatocytes are negative. 117 Antibody: Polyclonal Rabbit Anti-Human Von Willebrand Factor Code: IR527 or IS527 Clinical Application Reaction Location Recommended Control For identification of acute myeloid leukemia FAB type M7 (Fig. A) and angiosarcoma (Fig. B). Cytoplasm. Appendix/Colon: The endothelial cells of both blood and lymphatic vessels in lamina propria should show a moderate to strong staining reaction, while the epithelial cells should be negative (Fig. C). Liver: The endothelial cells lining the sinusoids should show a weak to moderate staining reaction, while the liver cells should be negative or only focally positive (Fig. D). The endothelial cells in the vessels in the portal areas should be distinctively demonstrated. Differential Diagnosis* 1. Angiosarcoma vs. carcinoma. 2. Subtyping of acute myeloid leukemia. * Differential diagnosis is aided by the results from a panel of antibodies. 118 Figure A. Acute myeloid leukemia (FAB type M7). The neoplastic cells show a strong predominantly cytoplasmic staining reaction. Figure B. Hemangiosarcoma. The majority of the neoplastic cells show a moderate to strong predominantly cytoplasmic staining reaction. Figure C. Colon. The endothelial cells of both blood and lymphatic vessels in lamina propria show a moderate to strong staining reaction. Figure D. Liver. The endothelial cells lining the sinusoids show a weak to moderate staining reaction. Antibody: Monoclonal Mouse Anti-Human Wilms’ Tumor 1 (WT1) Protein Clone: 6F-H2 Code: IR055 or IS055 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of Wilms’ tumor, malignant mesothelioma (Fig. A) and serous ovarian adenocarcinoma (Fig. B). Nucleus. Fallopian tube: Epithelial cells and the majority of the smooth muscle cells should show a moderate to strong nuclear staining reaction. A weak cytoplasmic background staining in these cells is accepted. Endothelial cells will typically show a moderate to strong cytoplasmic staining reaction (Fig. C). 1. Wilms’ tumor vs. neuroblastoma. 2. Peritoneal mesothelioma vs. serous carcinoma. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. Mesothelioma. The majority of the tumor cells show a strong nuclear staining reaction with no, or only a minimal, cytoplasmic or background staining reaction. Figure B. Ovarian serous adenocarcinoma. The majority of the neoplastic cells show a distinct nuclear staining reaction. A weak cytoplasmic staining reaction can also be seen in some cells. Figure C. Fallopian tube. The columnar epithelial cells and the muscle cells show a strong nuclear staining reaction. 119 Antibody: Monoclonal Mouse Anti-Human ZAP-70 Clone: 2F3.2 Code: IR653 or IS653 Clinical Application Reaction Location Recommended Control Differential Diagnosis* For identification of ZAP-70 in a subset of B-cell chronic lymphocytic leukemias/small lymphocytic lymphoma (Fig. A and Fig. B). Nucleus and cytoplasm. Tonsil: The isolated T cells in the germinal center should show a moderate to strong staining reaction, and the T cells in the T-zone should show a weak to moderate staining reaction (Fig. C). The germinal center B cells should be negative. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma with unmutated immunoglobulin gene vs. B-chronic lymphocytic leukemia/small lymphocytic lymphoma with mutation. * Differential diagnosis is aided by the results from a panel of antibodies. Figure A. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma with reaction associated with unmutated Ig heavy chain status. The majority of the neoplastic cells show a moderate to strong nuclear and cytoplasmic staining reaction. Figure C. Tonsil. The scattered T cells in the germinal center show a strong staining reaction, and the T cells in the T-zone show a moderate staining reaction. 120 Figure B. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma with reaction associated with mutated Ig heavy chain status. The neoplastic cells are negative, and only the T cells show a strong nuclear and cytoplasmic staining reaction. Australia +61 2 9922 0700 Canada +1 905 335 3256 France +33 1 64 53 61 44 Japan +81 3 5802 7211 Poland +48 58 661 1879 United Kingdom +44 (0)1 353 66 99 11 Austria +43 1 408 43 34 0 China +86 21 3612 7091 Germany +49 40 69 69 470 Korea +82 2 402 6775 Spain +34 93 499 05 06 United States of America +1 805 566 6655 www.dako.com Belgium +32 (0) 16 38 72 20 Denmark +45 44 85 97 56 Ireland +353 1 479 0568 The Netherlands +31 20 42 11 100 Sweden +46 8 556 20 600 Represented in more than 100 countries Brazil +55 11 50708300 Finland +358 9 348 73 950 Italy +39 02 58 078 1 Norway +47 23 14 05 40 Switzerland +41 41 760 11 66 Corporate Headquarters Denmark +45 44 85 95 00 00230 20JUL12 Relentless in our commitment to ighting cancer. Together.